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Hyperplasia leading to stenosis of synthetic vascular accesses for chronic hemodialysis 
is a widespread problem with no established treatment for prevention.  Inflammation around the 
anastomotic region in hemodialysis arteriovenous (AV) grafts is a constant reoccurring factor that 
likely contributes to hyperplasia development.  Perivascular delivery of an anti-inflammatory drug 
around the anastomotic region could be an effective option in preventing AV graft failure due to 
stenosis.  The objectives of this research were to investigate the involvement of inflammation in 
arteriovenous hemodialysis graft stenosis, ii) assess whether a novel drug, soluble epoxide 
hydrolase inhibitor (sEHI), would inhibit cytokine release from inflammatory cells; if so, sEHI may 
be useful to inhibit AV graft stenosis, and iii) to  develop a perivascular drug delivery system that 
could deliver a wide range of potential therapeutics in a directional and controlled manner to 
prevent AV graft stenosis.   
The first part of the dissertation investigates the involvement of inflammation in arteriovenous 
hemodialysis graft stenosis and if an experimental anti-inflammatory drug, sEHI, could be useful 
in inhibiting cytokine and chemokine release from primary macrophages.  In our porcine AV graft 
model, macrophage and T-cell accumulation increased over the 7 week time course 
corresponding with an increase in the hyperplasia formation at the venous anastomosis.  
Elevated expression of prominent cytokine/chemokines TNF- and MCP-1, was seen in vein-
graft anastomotic tissue.  The sEHI significantly inhibited LPS induced MCP-1 release and TNF- 
from primary macrophages.  The recruitment and activation of inflammatory cells around the graft 
anastomoses likely plays an influential role in causing hyperplasia in arteriovenous grafts and 
sEHI could be an effective therapeutic by preventing MCP-1 and TNF- release.   
 The second part of the dissertation is development of a perivascular delivery system for 
controlled and directed release of sunitinib, which could be utilized for other
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therapeutics.  A bilayer wrap design using either polycaprolactone or poly(lactic-co-glycolide) 
(PLGA) was produced containing a monolithic backing to provide unidirectional release and to 
prevent loss of drug to the extravascular space, and either a drug loaded non-porous layer, or a 
porous layer that could be filled with drug loaded hydrogel.  A biodegradable PLGA-based 
perivascular drug delivery system was created that provided early directed drug delivery and 
sustained release of sunitinib in vivo around the site of placement for at least four weeks. 
These results demonstrated that the bilayer PLGA wrap presented is a promising 
perivascular drug delivery system for the local treatment of arteriovenous graft hyperplasia.  sEHI 
could be useful to incorporate into this delivery system to target the recruitment of inflammatory 
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NEOINTIMAL HYPERPLASIA LEADING TO HEMODIALYSIS  
ARTERIOVENOUS GRAFT FAILURE 
1.1 General Introduction 
 Chronic kidney disease (CKD) is the progressive loss of the kidney’s ability to regulate 
electrolytes, remove waste from the blood, and concentrate urine.  Diabetes, hypertension, and 
glomerulonephritis are the most common causes of CKD, and continued progression of CKD can 
result in end-stage renal disease (ESRD), where there is a nearly complete or complete loss of 
kidney functions.  ESRD has commonly been treated with chronic hemodialysis, since it was 
made possible after the introduction of the external arteriovenous (AV) shunt in 1960 (1).  High 
extracorporeal blood flow rates reaching around 500 mL/min are necessary for a hemodialysis 
treatment of reasonable duration.  This requires vascular access to blood vessels that will permit 
high blood flow rates.   
There are currently three main types of vascular access used in hemodialysis: expanded 
polytetrafluoroethylene (ePTFE) AV grafts, native AV fistulas, and dual-lumen venous catheters 
(Table 1.1).  In ePTFE AV grafts, a length of synthetic graft is surgically connected between an 



















arm, but access can also be created in the leg, across the anterior chest wall as well as other 
locations.  AV fistulas are formed by connecting a vein directly to an artery, most frequently in the 
forearm, but also can be placed in the upper arm and upper leg around the groin (2).  An 
end-to-side design, where the end of a vein is sutured to the side of the artery, or a side-to-side 
design where the side of the vein is anastomosed to the side of the artery, are the standard fistula 
formats. Both the AV graft and AV fistula have served primarily as the permanent accesses for 
hemodialysis.  Dual-lumen venous catheters have an exceptionally high rate of thrombosis and 
infection and should be avoided if possible.  However, due to delayed referrals to nephrology 
specialists, and due to frequent failures of permanent accesses, catheter use for hemodialysis is 
still common.   
 Native AV fistulas are the preferred form of vascular access in hemodialysis because of 
the much lower rates of stenosis development and infection compared to other forms of vascular 
access.  This has led to the Centers of Medicare and Medicaid Services (CMS) and the ESRD 
Networks to implement the “Fistula First Initiative” pushing for increased AV fistula use in prevalent 
patients (patients already receiving dialysis) to 66% (3).  The prevalent rate for fistula use has 
increased from 43% reported in July 2006 to 59% in July 2011 (4).  The major limitation with the 
fistula is the failure of many new fistulas to mature into a useable access.  The term maturation in 
general describes the development of an access that can be readily located by dialysis staff for 
cannulation and obtains blood flow rates that will consistently allow hemodialysis sessions to occur 
in a reasonable time frame (3-4 hours).  The primary patency rate has been observed to be 85% 
after the first year and 75% after 2 years (5), but this data does not take into account the fistulas 
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that failed to mature into a viable access.  In a recent randomized trial conducted by the National 
Institutes of Health-sponsored Dialysis Access Consortium, almost 60% of newly created fistulas 
in 877 patients failed to mature within six months (6).  Several problems arise from the low 
maturation rates of native fistulas: Multiple attempts are required to create a sustainable fistula, 
which can deplete useable vascular sites.  While waiting for the fistula to mature, the need for 
venous catheter use persists increasing the risk of infection from the catheter and damage to 
catheterized vessels.                        
Within the last couple of years the placement of ePTFE AV grafts for hemodialysis has 
decreased considerably due to the “Fistula First Initiative” in the United States.  However, AV 
grafts have the advantage over AV fistulas that they can be used for dialysis shortly after placement 
as they require much shorter maturation times.  These accesses can be used within one or two 
weeks of creation compared to fistulas that can take months to mature.  The primary problem that 
plagues ePTFE grafts is the high rate of thrombosis that occurs due to underlying stenosis, which 
accounts for 85% of their failure (7).  Stenosis is characterized by neointimal hyperplasia (NH) 
formation, typically at the graft anastomoses, resulting in decreased blood flow and often eventual 
thrombosis (2).  The primary patency rate of AV grafts is quite low at around 50% at one year 
based on the data collected for the Dialysis Outcomes Quality Initiative (5).  Effective preventative 





1.2 Pathology of Hemodialysis Graft Stenosis 
 Stenosis due to the formation of NH in AV grafts occurs most commonly at the vein-graft 
anastomosis, the juxta-anastomotic venous segments, and with more limited occurrence at the 
arterial-graft anastomosis (2, 8-10).  NH that forms in AV grafts is characterized by: 1) the 
presence of smooth muscle cells and myofibroblasts (fibroblasts that have converted from 
differentiated, quiescent fibroblasts to a synthetic, contractile fibroblast), 2) an abundance of 
extracellular matrix, 3) microvessel formation (angiogenesis) within the NH and adventitia, and 4) 
the presence of macrophages and T-cells lining the ePTFE graft material.  Increased expression 
of growth factors like platelet-derived growth factor (PDGF), vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF), and transforming growth factor-1 (TGF-1) is seen 
within the venous NH (11-13).  Pathology of NH from porcine and canine AV graft models is similar 
to what is seen in humans (10, 14-16). 
 The contribution of myofibroblasts to the NH lesion has only been realized recently in AV graft 
NH (15, 17). Myofibroblasts play a significant role in hyperplasia by proliferating and migrating from 
the adventitia to the neointima, at which point they secrete extracellular matrix contributing to the 
mass of the hyperplastic lesion.  In our porcine AV graft model, presence of myofibroblasts was 
seen as early as one day after graft placement and marked proliferation and/or migration into the 
neointima occurred by two weeks.  It was found that these proliferating cells from the adventitia 
stained positive for smooth muscle -actin, a marker for both smooth muscle cell and fibroblasts, 
but negative for myosin heavy chain and smoothelin which are markers for smooth muscle cells 
(15).  Roy Chaudhury et al. confirmed these results by observing that the majority of cells found 
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within tissue segments from stenotic portions of human AV grafts were myofibroblasts (18).  The 
contribution of the adventitia, an outer layer of the vessel wall, to NH formation in the AV graft is of 
significance to these studies as it supports the logic of using perivascular delivery of drugs to inhibit 
NH. 
 Formation of NH is seen at both the arterial and venous graft anastomoses, but most of the 
stenosis occurs around the venous anastomosis with more limited occurrence at the arterial 
anastomosis (9).  There are several factors that likely make the venous side prone to more 
hyperplasia formation and stenosis.  The internal elastic lamina is much more defined in arteries, 
compared to veins.  The elastic lamina acts as a barrier to cell migration, thus its scarcity in vein 
may allow more ready migration of smooth muscle cells and myofibroblasts to the intima.  A 
decreased ability to produce prostacyclin and nitric oxide by veins may make them more 
susceptible to endothelial injury (2).  There is also significant disordered blood flow patterns and 
both low and very high sheer stress observed at the graft-vein anastomosis. As the vein normally 
experiences a much lower and steady blood flow, this novel introduction of arterial flow conditions 
likely contributes to an increased hyperplasic reaction as described below (19).  
1.3 Pathogenesis of Arteriovenous Graft Stenosis 
 Different initiating events and continuing aggravating factors contribute to the formation of NH 
in AV grafts.  The factors that cause endothelial and smooth muscle cell injury are upstream 
events that trigger the complicated downstream interplay between cytokines, growth factors, and 













the formation of NH in AV grafts include (1) surgical trauma to the vessel during graft placement; (2) 
placement of foreign ePTFE graft material leading to a foreign body response and mechanical 
mismatch between vessel wall and graft material; (3) introduction of novel hemodynamic stress at 
the vein-graft anastomosis; (4) repeated needle punctures of the graft for dialysis treatment leading 
to chronic injury and platelet activation; and (5) the presence of uremia causing endothelial 
dysfunction (2). 
1.3.1 Surgical Trauma 
A functioning endothelial cell layer produces prostacyclin (PGI2) and nitric oxide (NO) 
which inhibits the activation, aggregation, and adhesion of platelets to the endothelium (20).  
Surgical placement of the graft causes damage to the protective endothelium (intima) exposing 
medial smooth muscle cells to blood flow and other proinflammatory and procoagulation blood 
components.  Damage also occurs to the media and adventitia layers via surgical trauma as well 
as tissue hypoxia due to damage of the vaso vasorum.  This injury to the connective tissue initiates 
the inflammatory response recruiting inflammatory cells to the area where they release a variety of 
proinflammatory cytokines, growth factors, reactive oxygen species, and matrix metalloproteinases 
(MMPs) that promote proliferation and migration of smooth muscle cells and myofibroblasts.    
1.3.2 Biocompatibility Issues of ePTFE 
 The ePTFE graft materials were first introduced in 1973, and little advancement has been 
made in developing different biomaterials to use for AV grafts (21, 22).  One problem that persists 
with using ePTFE is the biocompatibility problems of the material that may contribute to 
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hyperplasia development.  Macrophages are commonly found in the NH at the vein-graft 
anastomosis particularly lining the ePTFE graft material (10, 13, 15).   The ePTFE is recognized 
as a foreign body to macrophages, which leads to their activation upon adherence.  Activated 
macrophages on ePTFE initially behave as classically activated macrophages where they release 
a variety of proinflammatory mediators, such as cytokines, growth factors, and MMPs that recruit 
other macrophages to the graft anastomosis and cause the proliferation and migration of SMCs 
and myofibroblasts.  This likely contributes to the formation of NH.  To support this idea, 
macrophages in the NH stained for PDGF, VEGF, and FGF in a porcine AV graft model (13).   
The formation of foreign body giant cells (FBGCs), which are also found in the anastomotic 
region (13, 23), arises from the fusion of macrophages due to “frustrated phagocytosis” on ePTFE 
(24).  FBGCs and macrophages adhered to biomaterials for extended periods of time (indication of 
chronic inflammation) switch phenotypes to an alternatively activated state (24, 25).  They produce 
anti-inflammatory cytokines (such as IL-10), reduce the release of proinflammatory cytokines, and 
generate pro-fibrogenic factors (such as TGF-1 and PDGF) that regulate fibrosis.  The 
phenotypes of adherent macrophages do not completely switch over time to alternative phenotypes 
as there is continued secretion of chemokines like monocyte chemotactic protein-1 (MCP-1) and 
RANTES (26).  FBGCs likely facilitate in hyperplasia formation by releasing TGF-1 and PDGF 
that cause myofibroblasts to increase extracellular matrix deposition at the anastomosis and these 
growth factors also recruit cells involved in NH to the anastomosis.  To support this notion, FBGCs 
also stained for PDGF, VEGF, and FGF in a porcine AV graft model and macrophages stained for 
TGF-1 in vein segments from human stenosed AV fistulas (27).  There is little published 
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information regarding macrophage response on ePTFE grafts in humans, and in vitro data has 
been relied upon to provide mechanistic insights into how the lack of biocompatibility of ePTFE 
factors into forming NH.   
 In vitro studies have shown ePTFE stimulation of macrophages might factor into several 
different biological processes that influence hyperplasia creation.  Rat vascular SMC proliferation 
was significantly increased by conditioned media from human peripheral blood monocytes cultured 
on ePTFE graft material (28).  Targeting tumor necrosis factor- (TNF-) using neutralizing 
antibodies inhibited this proliferative response indicating that TNF- plays a mitogenic role in the 
effect of ePTFE graft stimulation.  A human macrophage cell line (THP-1) cultured on ePTFE 
secreted TNF-, MCP-1, IL-6, MIP-1, and VEGF, all proinflammatory mediators that have been 
implicated in contributing to hyperplasia development (29).  Primary human macrophages 
maintained on ePTFE with varying pore size stimulated the release of IL-1 and the upregulation of 
IL-6, TNF-α, MCP-1, and MIP-1 emphasizing again that ePTFE stimulates macrophages to 
produce proinflammatory mediators that can stimulate the proliferation and migration of SMCs and 
myofibroblasts (30).  The biocompatibility problems of ePTFE also factors into angiogenesis and 
fibrogenesis, both processes that possibly assist in hyperplasia formation.  Angiogenesis provides 
to the NH a blood supply, and fibrogenesis facilitates an increased ECM deposition around the 
vein-graft anastomosis.  Human macrophages cultured on ePTFE released the pro-angiogenic 
factors VEGF and angiopoiten-1 and the conditioned media caused the sprouting of new blood 
capillaries from human placental blood vessel fragments (31).  Also activated human 
macrophages co-cultured with a fibroblast cell line (WI-38) increased fibroblast proliferation and 
11 
 
collagen synthesis as TGF-1 and PDGF production was elevated in the macrophages (32).   
Thus, recruitment and activation of macrophages by the ePTFE material may promote NH 
development in many different ways as described above.          
1.3.3 Hemodynamic and Mechanical Stresses  
Hemodynamic and mechanical stresses are likely important factors that lead to venous 
stenosis in AV grafts.  Hemodynamic stresses arise from the mechanical forces of blood on the 
vessel wall.  Blood flow produces a number of different stresses such as shear stress from the 
blood flow traveling over the stationary vessel wall, and strain from the blood pressure pushing 
against the vessel wall and expanding the lumen.  Areas at the graft-vein anastomoses experience 
a variety of unique shear stresses.  For example, the graft experiences pockets of low shear stress 
caused by disordered or stagnant flow resulting from the splitting of flow streams and other factors, 
which has been shown to stimulate smooth muscle cell proliferation.  High shear stress can 
damage the protective endothelial layer resulting in direct exposure of the smooth muscle layer to 
higher blood flow forces than it would normally experience and to coagulation factors from which it 
is normally protected (19, 33, 34).  Other non-flow induced stresses occur around the vein-graft 
anastomosis that arise from increased wall stress due to compliance mismatch between the stiff 
graft material and elastic native vein, and increased wall stress occurring at the suture line (35, 36).        
 There are three primary types of blood flow-induced stresses that cells in the vessel wall 
experience: 1) stress perpendicular to the vessel wall due to blood pressure as the blood travels in 
the vessel lumen, 2) circumferential wall stress leading to stretching of the compliant vessel wall 
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(37), and 3) “shear stress” as a result of the friction at the interface between luminal flowing blood 
and the endothelial cell surface.  Typically, luminal flow is only experienced by endothelial cells, 
but upon vessel injury due to graft placement, SMC and possibly fibroblasts become exposed to 
flow.  These types of hemodynamic stresses regulate the remodeling and function of the vascular 
wall, which also factor into other various pathological conditions (38-41).  At the vein-graft 
anastomosis and other areas prone to hyperplasia, blood flow patterns are quite complex and are 
characterized by disordered flow, flow separation or flow split, low shear stress, and stagnation 
vortices or eddies (42-46).  Most flow data available are derived from flow rates at only a few 
locations around the anastomosis and outside the anastomosis (34).  More detailed studies are 
needed in order to thoroughly characterize the flow in the areas that are prone to hyperplasia in AV 
grafts.        
 Depending on the type of blood flow stress, the possible contributing affect on AV graft 
stenosis could be considered either negative or positive.  In atheroma formation, low shear stress 
has been associated with SMC proliferation as first suggested in 1969 (47). Subsequent in vivo 
studies have confirmed this finding and suggest it may be due to the upregulation of PDGF 
expression (48, 49).  However, higher shear stress inhibits SMC proliferation (50) possibly through 
TGF-1 upregulation in an autocrine manner (51, 52).  The question is how these findings 
translate to venous SMCs, since stenosis occurs more at the vein-graft anastomosis than arterial.  
Additionally, the effect of the very complex flow patterns that occur at the vessel-graft anastomosis 
or juxta-anastomosis segments on venous or arterial SMCs is not known.  
The anastomosis region experiences increased tensile wall stress.  After graft placement, 
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blood pressure and wall stress values can increase an order of magnitude on the venous side to 
levels similar to arterial blood flow and wall stress (37).  Compliance mismatch between the 
elastic native tissue and stiff graft material and suture materials further elevates wall stress on both 
the venous and arterial sides of the AV ePTFE graft.  A positive correlation is seen between 
tensile wall stress and cell proliferation (53-56).  It has been debated whether it is increased 
strain or increased ensuing cellular stiffness that stimulates enhanced cell proliferation (57-59), but 
it is commonly accepted that wall tensile strain induces cell proliferation.  Since the venous side 
in AV grafts undergoes a larger increase in circumferential wall strain, this likely makes it more 
prone to hyperplasia formation than the arterial.   
1.3.4 Repeated Puncturing for Dialysis 
 Reccurring platelet activation due to repeated needle punctures of the ePTFE graft material for 
dialysis treatment contributes to chronic inflammation around the anastomosis.  The resulting 
platelet thrombus that forms after dialysis needle removal causes the upregulation and secretion of 
PDGF and other cytokines.  The downstream anastomosis then becomes exposed to these 
proinflammatory mediators that have the ability to elicit the recruitment and activation of 
macrophages and that promote proliferation and migration of SMCs and myofibroblasts.  Chronic 
inflammation ensues due to repeated puncturing needed for dialysis three times a week, 





1.3.5 Downstream Events 
The endothelial and SMC response to injury is what instigates the downstream events that 
form NH.  This injury response triggers SMCs and myofibroblasts to migrate from the media and 
adventitia to the intima region.  At the intima, they proliferate and deposit ECM that contributes 
significantly to NH formation.  While this is occurring, inflammatory cells adhere to and extravasate 
through damaged endothelial cells at the injury site.  Neutrophils accumulate first (61) followed by 
macrophages (62).  Numerous inflammatory mediators orchestrate these various responses.  
Each one of these mediators is a potential therapeutic target that could help alleviate hyperplasia at 
the anastomotic regions.        
 Inflammation plays a key role in hyperplasia formation and proinflammatory cytokines such as 
TNF- contribute to this process.  TNF-is synthesized by several key cell types relevant to NH, 
including macrophages, T-cells, endothelial cells, SMCs, and fibroblasts (63, 64).  TNF can initiate 
processes linked to NH such as smooth muscle cell migration (65) and proliferation (63), matrix 
degradation (66) , and production of intercellular adhesion molecule-1 (ICAM-1) (67), MCP-1, and 
growth factors (PDGF, VEGF, and bFGF) (68).  A number of studies suggest a primary role for 
TNF in NH formation.  For example, after balloon injury of a rat aorta, increased levels of TNF- 
were observed several days prior to the migration of smooth muscle cells into the intima (65).  
Additionally, basal TNF- levels were significantly higher in Korean patients that had vascular 
access failure compared to the group with functioning vascular accesses (69).  This supporting 
evidence indicates that TNF- might play a pivotal role in NH development that leads to stenosis of 
AV grafts.   
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 MCP-1 (CCL2), a CC chemokine, is a potent chemoattractant that recruits peripheral 
monocytes and memory T-cells into sites of inflammation (70).  Besides monocytes/macrophages, 
many other cell types secrete MCP-1 including T-cells, endothelial cells, smooth muscle cells, and 
fibroblasts (71); all cell types that likely play a role in hyperplasia formation.  Increased MCP-1 
expression has been reported within the vascular wall of atherosclerotic lesions (72, 73) and in 
injured arterial walls upon balloon injury (74, 75), which corresponded with the increased 
accumulation of macrophages to the injured site.  Inhibiting MCP-1 using either a neutralizing 
antibody for MCP-1 or a plasmid coding for an N-terminal deletion mutant MCP-1 has been 
effective in diminishing NH in different animal models of arterial injury (75-83).  Recently, MCP-1 
was shown to be upregulated in a mouse AV fistula model. MCP-1 knockout mice had increased 
fistula patency and a decrease in wall thickness at 6 weeks after fistula creation compared to 
wild-type mice, implicating a role for MCP-1 in vascular access dysfunction (84).  Currently, 
substantial efforts are being made to develop a clinically useful treatment strategy to prevent the 
mechanism of action of MCP-1 (85-87); such a treatment could be beneficial in inhibiting AV graft 
stenosis.    
 PDGF plays a part in each stage of the wound healing response.  Upon injury PDGF is 
released from activated platelets and this stimulates the chemotaxis and mitogenicity of 
neutrophils, macrophages, SMCs, and myofibroblasts to the injury site around the graft 
anastomosis (11, 88, 89). It also increases the formation of granulation tissue (ECM deposition) by 
causing the proliferation of fibroblasts and inducing the myofibroblast phenotype (90), which likely 
increases ECM in the anastomotic region.  Typically, PDGF is not expressed in the normal 
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vasculature, but upon endothelial injury after angioplasty or graft placement, PDGF becomes 
upregulated along with its receptors (12, 13, 91).  Ferns et al. showed that inhibition of PDGF 
using a PDGF-specific monoclonal antibody attenuated NH in a rat arterial injury model (92).  
Thus, using pharmacological inhibitors that target PDGF or the PDGF receptors would be a 
reasonable strategy in trying to prevent AV graft stenosis.   
 Breakdown of ECM proteins like collagen and elastin by MMPs (zinc dependent proteases), 
particularly MMP-2 and MMP-9, is a prerequisite for migration of SMCs.  As the ECM is broken 
down by MMPs, it allows the SMCs to migrate from the media into the intima contributing to NH 
formation.  Several cell types that have been associated with hyperplasia produce MMPs, such as 
endothelial cells, macrophages, SMCs and fibroblasts (93).  MMPs are activated by increased flow 
and vascular injury (94, 95).  Inhibition of MMP production should then in theory lead to a reduced 
amount of SMCs accumulating in NH.  An experimental MMP inhibitor (BB2983) that was given 
orally significantly lessened NH formation when compared to untreated in a porcine AV graft model 
(96).  However, one problem that has limited the use of MMP inhibitors clinically is the 
development of musculoskeletal toxicity observed in various clinical trials with these drugs (97, 98).    
 Arachidonic acid (AA), a polyunsaturated fatty acid, can be metabolized to form both 
proinflammatory and anti-inflammatory mediators.  Cyclooxygenase (COX) and lipoxygenase 
(LOX) convert AA into prostaglandins and leukotrienes, of which many are potent lipid inflammatory 
mediators that can cause SMC proliferation and migration, platelet aggregation, and inflammatory 
cell adhesion (99-101).  Elevated levels of both COX and LOX are observed in patients with 
atherosclerosis (102, 103).  Targeting both enzymes using licofelone, a dual COX and LOX 
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antagonist, inhibited inflammation and neointimal formation in an atherosclerotic rabbit model 
(104).  For these reasons, the COX and LOX pathways may be alternative therapeutic targets in 
the treatment of AV graft stenosis.     
1.4 Treatment and Preventative Strategies for 
Neointimal Hyperplasia Formation 
 A better understanding of the pathogenesis leading to NH formation exists, which has helped 
in identifying potential therapeutic strategies that are useful in combating this problem.  Several 
strategies to inhibit NH have been created and shown efficacious in various animal models, 
including some specifically focused on hyperplasia development in AV grafts.  However, there 
currently is no effective treatment in preventing AV graft stenosis in hemodialysis patients.   
The current first-line treatment of AV graft stenosis is percutaneous transluminal angioplasty 
(PTA).  Initial studies revealed that PTA was an effective option that prolonged vascular access 
use in all types of venous stenoses (105, 106).  Beathard reported a 94% initial success rate and 
primary patency rates of 90.6%, 61.3%, and 38.2% at 90, 180, and 360 days after angioplasty in 
hemodialysis patients with AV graft stenosis (105).  Yet, balloon injury to the vascular wall 
promotes NH growth, which commonly leads to restenosis after coronary angioplasty (107, 108).    
Chang et al, demonstrated by immunohistochemistry increased cellular proliferation in restenotic 
lesions formed after PTA of AV fistula compared to primary stenotic lesions (109).  In contrast to 
results reported by Beathard and others, a number of randomized clinical trials reported that 
treatment of AV grafts with prophylactic PTA failed to demonstrate any improvement in patency 
(110-112).                    
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 Mechanical device interventions such as bare metal or drug eluting stents are routinely 
employed after angioplasty to prevent coronary restenosis.  Stent placement after PTA has been 
investigated as a potential treatment to target stenosis at the vein-graft anastomosis.  Early 
randomized controlled trials failed to show any benefit of bare metal stents over PTA alone in AV 
grafts (113, 114). Recently a large multicenter, randomized, clinical trial by Haskal et al. detailed 
improved patency rates of stent grafts (nitinol stent covered in carbon-impregnated ePTFE) versus 
PTA alone in the treatment of stenosis at the venous anastomosis (115).  At 6 months, patency in 
the stent graft group was 51% compared to 23% in the PTA group.  However, thrombosis rates 
were comparable between stent (33% occlusion) and unstented (21% occlusion) groups at six 
months after stent graft placement with a trend that was actually worse in the stent treated group.  
Although stent grafts are currently used in hemodialysis access there is not any conclusive 
evidence that supports their benefit.  There currently is not any clinical data using drug-eluting 
stents with PTA to prevent stenosis in AV graft vascular access.  Promising results have been 
reported in a porcine AV graft model.  Rapamycin-eluting stents but not bare metal stents 
significantly diminished hyperplasia and increased blood flow rate and graft diameter, compared to 
unstented grafts (116).                       
 Delivery of biological and small molecule agents can be accomplished by systemic or local 
administration in order to treat AV graft stenosis.  Two large multicenter trials that recently ended, 
evaluated the effect of systemically delivered anti-platelet agents (clopidogrel or dypridamole and 
aspirin) on preventing dialysis access stenosis.  In the native AV fistula study, clopidogrel was 
able to significantly reduce the early occurrence of thrombosis in AV fistulas at 6 weeks, but did not 
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increase the proportion of AV fistulas that were suitable for dialysis (6).  In the AV graft study, an 
oral combination of dipyridamole and aspirin reported a modest, but statistically significant 
improvement in unassisted patency rate in the treatment group (28%) compared to placebo (23%) 
at one year (117).  These results raise the question if conventional systemic therapies can be 
successful in treating the complex and aggressive stenosis in AV grafts.             
 Local perivascular delivery circumvents many problems with systemic delivery.  Local 
delivery to the site of stenosis can achieve greater local concentrations using a lower dose, 
minimizing undesired systemic toxicity.  Drug placed directly around the “active adventitia” might 
be more effective in inhibiting activation and migration of fibroblasts (2).  Various localized 
delivery approaches have been utilized: 1) placing a drug-eluting stent perivascularly at the 
anastomoses (116), 2) coating the ePTFE graft with drug and using it as a delivery conduit (118, 
119), 3) placing an intravascular catheter at time of graft placement that can be used to inject drug 
into the anastomotic region (120), and 4) placing a drug depot such as a perivascular wrap (121, 
122) or a polymer gel (14, 123, 124) around the anastomoses.       
1.4.1 Biological Therapies 
 Cell-based therapy using allogeneic endothelial cell-loaded gelfoam perivascular wraps to 
prevent vascular access stenosis has been under investigation for the last decade.  The reasoning 
behind using these endothelial cell implants is that endothelial cells can generate numerous 
beneficial mediators that in combination may inhibit cell proliferation and migration (125).  In a 
porcine AV ePTFE graft model, endothelial cell-loaded wraps did not cause a significant decrease 
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in NH at 28 days, but there was increased venous lumen diameter and positive remodeling, and an 
81% decrease in stenosis compared with controls (125).  In a multicenter phase II trial, the safety 
of these wraps were demonstrated in hemodialysis patients with AV grafts, however, there was no 
statistically significant difference in primary and unassisted patency rates compared to placebo 
(126).  Successful endothelialization of ePTFE by endothelial cell seeding could be beneficial in 
improving graft patency and has been shown to be effective in prosthetic bypass grafts in clinical 
trials (127).  Rotmans et al. immobilized anti-CD34 on ePTFE grafts in order to capture endothelial 
progenitor cells in a porcine AV graft model (128).  Successful endothelialization was 
accomplished using this method.  However despite that, NH formation was significantly increased 
with these grafts at 4 weeks compared to untreated controls.  These results raise doubt that 
endothelial cell-based therapies can be effective in NH prevention.  
 Anti-proliferative gene therapy strategies delivered locally could be an effective option in NH 
treatment.  Antisense oligodeoxynucleotides (ODNs) targeting specific genes involved in cell 
proliferation can be generated, which can inhibit DNA transcription, formation of mature RNA, and 
protein synthesis.  A number of studies using antisense ODNs have demonstrated inhibition of NH 
in arterial injury models by directly targeting PDGF- receptor subunit, c-myc, proliferating cell 
nuclear antigen, cyclin-dependent kinase 2, nuclear factor-B, and the transcription factors (E2F) 
(129-134).  Large randomized trials using decoy ODNs targeting E2F following peripheral or 
coronary artery bypass grafting (PREVENT III and IV) (135, 136) failed to show efficacy in 
preventing vein graft failure even though success was seen in smaller randomized trials (137).  A 
clinical phase I trial using the E2F decoy in hemodialysis patients with AV grafts was completed, but 
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further studies were halted due to the poor response in the PREVENT III and IV studies.  Other 
gene therapy strategies to promote endothelialization by delivery of adenovirus encoding for 
VEGF-C, inhibited NH in angioplasty-induced restenosis in animal models (138).  In contrast, 
other studies in various animal models that used either adenovirus coding for VEGF-A and 
VEGF-D, or delivery of VEGF-A protein from a fibrin coated graft, showed enhanced NH 
progression (139, 140).  Enrollment of hemodialysis AV graft patients for a clinical phase III trial 
using adenovirus coding for VEGF-D to prevent stenosis was underway in 2009 since phase I/II 
studies exhibited technical feasibility and safety of the treatment (120).    
1.4.2 Small Molecule Therapies 
 The use of small molecule drugs for treatment of NH has an advantage over biological 
therapies in that they are simpler agents and are unlikely to initiate a host immune response.  
Drugs that were used in first generation drug-eluting stents such as rapamycin and paclitaxel have 
garnered the most interest in perivascular delivery applications to deal with AV graft stenosis.  
Three other small molecules that will be discussed are nitric oxide, imatinib mesylate, and soluble 
epoxide hydrolase inhibitors.           
Rapamycin, a potent immunosuppressant, inhibits cell cycle progression from the G1 to S 
phase by complexing to FK506 binding protein (FKBP12), which causes inhibition of mammalian 
target of rapamycin (m-TOR) (141).  It is used clinically to prevent allograft rejection by 
T-lymphocytes and employed in drug-eluting stents to thwart coronary restenosis after balloon 
angioplasty. Two large randomized trials (RAVEL and SIRIUS trials) proved that rapamycin-eluting 
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stents could decrease restenosis rates after angioplasty and major adverse cardiac events in 
patients (142) even five years post study (RAVEL) (143).  One study as discussed earlier has 
provided insight into the ability of rapamycin-eluting stents to prevent NH in a porcine AV graft 
model (116).  This study is promising, but there are some possible disadvantages with using a 
stent in treating NH in AV grafts.  Drug-eluting stent placement is an invasive technique with only a 
limited duration of drug release available from the depot.  The drug depot cannot be replenished in 
stents, which might limit the effectiveness against AV graft NH in which chronic pathogenic factors, 
and not a single insult such as angioplasty, contribute to the NH.  In another study in a porcine AV 
graft model, rapamycin coated onto the ends of ePTFE using mixed methacrylates inhibited NH for 
four weeks (118).  COLL-R
®
, a rapamycin-eluting collagen wrap, finished phase II trials in 
hemodialysis patients with AV grafts.  Unassisted primary patency rates of 75% and 38% at one 
and two years were reported (120), which is better than the 50% patency rate stated for AV grafts at 
one year without any pharmacological interventions. 
Paclitaxel is a mitotic inhibitor that stabilizes the mitotic spindle blocking cell division and 
migration.  Just like the rapamycin drug-eluting stent, numerous clinical studies (TAXUS I – 
TAXUS VI, ASPECT, and ELUTES trials) have verified the effectiveness and safety of 
paclitaxel-coated stents to inhibit restenosis and in-stent stenosis after balloon angioplasty in 
coronary arteries (144-148).  Our group has demonstrated the ability of a paclitaxel-loaded 
thermosensitive polymer, liquid at 4 
o
C then gels at 37 
o
C, placed perivascularly around the venous 
anastomosis could attenuate hyperplasia formation in a canine AV graft model (14).  Recently, 
perivascular wraps laden with paclitaxel positioned around the anastomoses inhibited NH creation 
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in both porcine (121) and sheep (122) AV graft models.  A large multicenter trial was underway 
testing the efficacy of a PLGA-based paclitaxel eluting wrap in preventing stenosis in AV grafts, but 
was halted due to an imbalance in the incidence of infections in one of the study arms (either the 
control or treatment group) (120).  The sponsor was blinded to the treatment group thus it was not 
reported if it was the wrap-treated group that experienced the increased incidence of infection.                  
Nitric oxide (NO) is able to inhibit several key pathways involved in the progression of 
hyperplasia in AV grafts, including platelet activation, SMC proliferation and migration, and ECM 
synthesis (149).  NO inhibited SMC proliferation in vitro (150) and in balloon injury models in both 
rat (151) and porcine (152) through cyclic guanosine monophosphate (cGMP)-dependent 
mechanisms.  Stents eluting an NO donor or NO releasing compound (sodium nitroprusside) 
diminished restenosis in a rabbit (153) and porcine (154) balloon angioplasty injury models.  NO 
generating polymeric hydrogels placed perivascularly suppressed hyperplasia development by 
80% compared to controls in a rat carotid balloon injury model (149).  Currently, no studies have 
been reported investigating the effect of NO delivery to prevent AV graft stenosis. 
As discussed previously, PDGF is a potent chemoattractant and mitogen that plays an 
essential role in initiating SMC migration and proliferation (11, 88).  Imatinib mesylate, a tyrosine 
kinase inhibitor that inhibits both PDGF receptor subtypes has been shown to inhibit restenosis 
after balloon angioplasty (155) and diet-induced atherosclerosis (156).  Data obtained in our lab 
has demonstrated the ability of imatinib to deter both arterial and venous SMC proliferation, with 
increased potency (eight fold lower IC50) in venous cells compared to arterial (157).   Tyrosine 
kinase inhibitors with similar mechanisms of action as imatinib should also possibly be effective 
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against NH formation.  Sunitinib is a multitarget receptor tyrosine kinase inhibitor of both PDGF 
receptor subtypes, all three VEGF receptor subtypes, KIT, FLT3, and CSR-1R (158).  Sunitinib is 
currently FDA approved to treat gastrointestinal stromal tumors and metastatic renal cell 
carcinoma.  Currently, the therapeutic efficacy of sunitinib in preventing hyperplasia formation has 
not been analyzed.  Data from our laboratory have verified the ability of sunitinib to inhibit PDGF 
stimulated proliferation of human venous SMCs in vitro (IC50~5 nM; manuscript in preparation).  
These findings suggest that both imatinib and sunitinib could be promising drugs to use in 
preventing AV graft stenosis.     
AA can be metabolized to epoxyeicosatrienoic acids (EETs) by a third pathway involving the 
epoxygenase cytochrome P450 enzymes, particularly CYP2C and 2J.  EETs have 
anti-inflammatory properties and are important modulators of vascular function.  Experimental 
evidence indicates that EETs elicit their anti-inflammatory effects by inhibiting the activation of 
NF-B (159), a key transcriptional factor that causes the upregulation of numerous proinflammatory 
genes.  For example, EETs inhibit the expression of vascular cell adhesion molecule-1 (VCAM-1) 
in human endothelial cells in response to TNF, interleukin-1-alpha (IL-1 or lipopolysaccharide 
(LPS) (159).  EETs also inhibit other important biological processes that contribute to NH such as 
SMC migration (160) and platelet aggregation (161).  However, soluble epoxide hydrolase (sEH) 
quickly metabolizes EETs to the less active dihydroxyeicosatrienoic acids (DHETs).  Potent and 
selective pharmacological inhibitors (soluble epoxide hydrolase inhibitors or sEHI) (162, 163) have 
been developed, which increase and extend the functional effects of EETs.  Several studies have 
demonstrated the anti-inflammatory effects of these inhibitors after systemic administration (164, 
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165).  We investigated the potential of these inhibitors as a possible therapeutic to prevent NH by 
examining their effects on inhibiting cytokine release from inflammatory cells (discussed in further 
detail in Chapter Two).    
1.5 Statement of Objectives 
 The primary objectives of this work are to i) investigate the involvement of inflammation in 
arteriovenous hemodialysis graft stenosis, ii) assess whether a novel drug, a soluble epoxide 
hydrolase inhibitor (sEHI), would inhibit cytokine release from inflammatory cells; if so, sEHI may 
be useful to inhibit AV graft stenosis, and iii) to develop a perivascular drug delivery system that 
could deliver a wide range of potential therapeutics in a directional and controlled manner to treat 
AV graft stenosis.  The fundamental hypothesis driving these objectives is that perivascular 
delivery of an anti-inflammatory drug around the anastomotic region could be an effective option in 
preventing AV graft stenosis.                         
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ANTI-INFLAMMATORY EFFECTS OF A PHARMACOLOGICAL INHIBITOR OF  
SOLUBLE EPOXIDE HYDROLASE 
2.1 Introduction 
 The eicosanoid signaling molecules, epoxyeicosatrienoic acids (EETs), are products of the 
epoxidation of arachidonic acid by cytochrome P450 enzymes.  EETs have anti-inflammatory 
properties and are important modulators of vascular function.  For example, EETs are reported to 
inhibit the activation of nuclear factor kappa B (NF-B) (1), a key transcription factor involved in the 
expression of numerous pro-inflammatory genes.  EETs inhibit the expression of vascular cell 
adhesion molecule-1 (VCAM-1) in human endothelial cells in response to tumor necrosis 
factor-alpha (TNF-), interleukin-1-alpha (IL-1), or lipopolysaccharide (LPS) (1).  EETs also 
induce vasodilation (2-4), inhibit the migration of rat aortic vascular smooth muscle cells in 
response to platelet-derived growth factor (5), inhibit platelet aggregation and activation (6), and 
induce endothelial cell proliferation (7).  However, the intracellular enzyme soluble epoxide 
hydrolase (sEH) quickly metabolizes EETs to the less active dihydroxyeicosatrienoic acids 
(DHETs).  Soluble epoxide hydrolase is broadly distributed in mammalian tissue although liver 
has the highest activity (8).  Potent and selective pharmacological inhibitors (soluble epoxide 
hydrolase inhibitors or sEHI) have been developed (9, 10) and have been shown in some animal 
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models to have anti-hypertensive effects and to protect against end-organ damage due to 
hypertension and other cardiovascular disease (11).  In addition, systemic exposure to sEHIs 
have been reported to (i) prevent mortality and reduce plasma levels of IL-6 and monocyte 
chemotactic protein-5 (MCP-5) in mice after intraperitoneal injection of a typically lethal dose of 
LPS (12), (ii) decrease macrophage recruitment to glomeruli in hypertensive rats (13), (iii) 
decrease the number of inflammatory cells present in bronchial lavage samples from rats exposed 
to tobacco smoke (14), (iv) and significantly inhibit urinary monocyte chemotactic protein-1 
(MCP-1) levels in a rat model of hypertension (15).  Together these data support the notion that 
sEHIs may be anti-inflammatory and could be particularly useful in the treatment of vascular 
inflammation. 
Inflammation likely plays a role in the pathology of many vascular disorders such as 
atherosclerosis (16), restenosis after balloon angioplasty of stenotic lesions (17), failure of vein 
bypass grafts (18, 19), and the development of hyperplasia within vascular accesses for chronic 
hemodialysis (20, 21).  Chronic hemodialysis requires access to high rates of blood flow, often 
achieved by the placement of synthetic tubing between an artery and a vein.  Unfortunately 
approximately 50% of such synthetic vascular accesses fail due to stenosis at the juncture of the 
vein and graft, and treatment strategies are needed to inhibit graft failure.  In the current work we 
characterized inflammation and sEH expression in an animal model of synthetic vascular access 
graft stenosis.  We then tested the effects of sEHI on the release of various inflammatory 
chemokine/cytokines from primary human monocyte/macrophages with the goal of determining if 
sEHIs could be an effective treatment for hemodialysis vascular access graft stenosis.  To our 
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knowledge this is the first report on the effects of sEHI on the production of inflammatory 
cytokines/chemokines from isolated monocyte/macrophages. 
2.2 Materials and Methods 
2.2.1 Materials 
sEHI cis-4-{4-[3(4-trifluoromethoxyphenyl)ureido]cyclohexyloxy}-benzoic acid (c-TUCB) 
(Figure 2.1) was synthesized by the laboratory of Dr. Bruce Hammock (22).  Epoxyeicosatrienoic 
acids (EETs) 8,9-EET, 11,12-EET and 14,15-EET were purchased from Caymen Chemical (Ann 
Arbor, MI).  Flow cytometry antibodies were purchased from BD Biosciences (San Jose, CA).  
Serum free media (SFM) was from Invitrogen (Grand Island, NY).  Lipopolysaccharide (LPS) 
(055:B5) was from Sigma-Aldrich (St. Louis, MO).  Polyclonal rabbit anti-porcine-sEH antibody 
(23) for tissue immunostaining was generated in the laboratory of Dr. Bruce Hammock against 
recombinant porcine sEH.  Polyclonal rabbit anti-human sEH antibody raised against an internal 
region of human sEH and blocking peptide (Santa Cruz, CA) were used for immunocytochemical 
staining and western immunoblotting.  Polyclonal rabbit anti-human CD3, polyclonal rabbit 
anti-human myeloperoxidase, and polyclonal rabbit anti-human PAX5 were from Cell Marque 
(Rocklin MA).  Polyclonal rabbit anti-pig MCP-1 (CCL2) was from Bethyl Laboratories 
(Montgomery, TX). Monoclonal mouse anti-pig phospho-inhibitory B (IB), monoclonal rabbit 
anti-human NF-B p65, and polyclonal rabbit anti-human phospho-stress activated protein kinase 















purchased from Cell Signaling Technology (Danvers MA). 
2.2.2 Animal Model 
A porcine arteriovenous (AV) expanded polytetrafluoroethylene (ePTFE) graft model was 
utilized as described in previous studies (24).  Briefly, three month old Yorkshire cross-domestic 
swine (~30kg) were anesthetized using a mixture of ketamine (4mg/kg; Hospira Inc., Lake Forest, 
IL), xylazine (4 mg/kg; Lloyd Laboratories, Shenandoah, IA), and tiletamine/zolazepam (4mg/kg; 
Fort Dodge Animal Health, Fort Dodge, IA).  To maintain anesthesia, 1-3% isoflurane was 
administered via tracheal intubation.  Sodium heparin (100 U/kg) was given by a bolus 
intravenous injection intra-operatively.  Sterile spiral reinforced ePTFE graft (7-cm in length, 
6-mm internal diameter) was sutured in place between the ipsilateral external jugular vein and the 
common carotid artery.  After verification of patency and hemostasis, the wound was closed and 
the animals were maintained until euthanasia as indicated below.  All animal work was performed 
using protocols approved by the Institutional Animal Care and Use Committee of the University of 
Utah and Veterans Affairs Salt Lake City Healthcare System and followed guidelines specified by 
the Guidelines for the Care and Use of Laboratory Animals.   
The animals were euthanized at designated time points: 1 day, and 1, 2, 3, 4, 6, and 7 weeks 
after graft placement.  The graft with connected artery and vein were explanted en bloc, fixed, 
and embedded in paraffin as previously described (24, 25).  Briefly, after surgical exposure of the 
grafts in anesthetized animals, heparin was administered (200 U/kg), the artery was cannulated 
and the lumen of the grafts and adjoining artery and vein were rinsed with saline.  The animals 
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were euthanized by intravenous injection of pentobarbital sodium (80-100 mg/kg) and the grafts 
and attached vessels were perfused in situ with 10% zinc formalin.  The artery and veins were 
ligated under physiologic pressure to maintain lumen circumference then explanted en bloc and 
further fixed in formalin overnight.  The tissue was paraffin-embedded and 5-m sections were 
cut perpendicular to the vein lumen (as illustrated in Figure 2.2) and processed for immunostaining 
using standard techniques. 
2.2.3 Neointimal hyperplasia (NH) Index 
The surface area of hyperplastic tissue within 5-m cross-sections of the AV graft was 
manually quantified in tissue stained with Elastin von Gieson as previously described (25).  The 
NH index was defined as: the sum of the intimal hyperplasia within the lumen of the ePTFE graft 
(region delineated by dashed lines in Figure 2.2A) and the hyperplasia within the native vein wall, 
and divided by the sum of the medial area in the native vein wall and the PTFE graft area in the 
same tissue cross-section. The hyperplastic tissue area was divided by the medial and PTFE graft 
area to normalize for the angle at which the tissue section was obtained. 
2.2.4 Tissue Immunostaining 
Formalin-fixed paraffin-embedded tissue sections from the vein-graft anastomosis region 
were dewaxed and rehydrated following standard protocols. Tissue sections were immunostained 
with anti-CD3 (1:1000), anti-PAX-5 (undiluted), and anti-myeloperoxidase (1:1000) antibodies to 
detect T lymphocytes, B lymphocytes, and neutrophils respectively. Immunostaining with 































Fig 2.2 Foreign body giant cell (FBGC) and T-lymphocyte accumulation in AV graft hyperplasia.  
Hyperplastic tissue (outlined by the dashed line in “A”) in histological cross-sections obtained from 
pigs euthanized at various time points after graft placement (one to 49 days) was assessed for 
T-lymphocytes by immunostaining with anti-CD3 antibody (‘B’ rust color), and FBGC, by 
immunostaining with anti-phospho-IB followed by visual assessment of multinucleated cells (‘C’ 
white arrow).  CD3+ cells and FBGC accumulation in the vein-graft anastomoses was plotted 
over time (left y-axis) (D). Neointimal hyperplasia (NH) was assessed in tissue sections as 
described in Methods and plotted over time (right y-axis) and correlated with inflammatory cell 





ungrafted porcine external jugular vein, and vein-graft anastomotic tissue collected at 1 day and 1, 
2, 3, 4, 6 and 7 weeks after graft placement. For T and B lymphocyte, neutrophil detection and 
phospho-IB detection, antigen retrieval was performed in Trilogy solution (CellMarque) by heating 
at 100 
o
C for 15 min (EZ retriever system, BioGenex Laboratories Inc., San Ramon, CA).  Tissue 
sections were blocked with 2% goat serum for one hr at room temperature (RT) and incubated with 
antibodies at 4 
o
C overnight.  Antibody binding was detected with HRP-conjugated anti-rabbit and 
DAB chromogen following the manufacturer’s protocol (Envision Systems, DAKO, Carpenteria, 
CA) and sections were counterstained with hemotoxylin.  For MCP-1 expression, a previously 
published protocol with minor modifications was followed (26).  Briefly, heat-induced antigen 
retrieval was performed on tissue sections by heating to 95 
o
C for 15 min in Tris-EDTA buffer (pH 
9.0) (EZ-Retriever System). Tissue sections were blocked with 2% goat serum for 1 hr at RT and 
then incubated with antibody overnight at 4 
o
C. Sections were then washed three times with 
0.05%Tween/PBS and incubated with biotinylated anti-rabbit IgG (1:200) for 1 hr at RT followed by 
incubation with streptavidin Alexa-fluor 546 (1:200) (Invitrogen, Carlsbad, CA) for 1 hr at RT in the 
dark.  Nuclei were stained using DAPI Fluoromount (Southern Biotech, Birmingham, AL). 
2.2.5 Monocyte Isolation and Cell Culture 
Peripheral blood mononuclear cells (PBMC) were obtained from the heparin anticoagulated 
blood of healthy adult volunteers using Ficoll-Hypaque (GE Healthcare, Piscataway, NJ) density 
gradient centrifugation following the manufacturer’s protocol. Monocytes were isolated by 
adherence to tissue culture plastic during a 2-hr incubation in SFM culture media plus 20% 
autologous serum.  The non-adherent cells were then removed by repeat washing with 1x 
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phosphate-buffered saline (PBS). The remaining adherent cell population was enriched in 
monocytes as determined by flow cytometry assessment of immunostained cells using standard 
techniques; typically ≥70% monocytes, ≤10% CD3+ T-lymphocytes, ≤1% B-lymphocytes, ≤8% 
natural killer cells, and <1% neutrophils were observed in each isolation.  Isolation of PBMCs 
from blood from adult volunteers was performed using protocols approved by the Institutional 
Review Board of the University of Utah and Veterans Affairs Salt Lake City Healthcare System.   
The adherent cells were dislodged from the plastic after incubation for 15 min with calcium- 





) in SFM with 20% autologous serum.  c-TUCB was dissolved in dimethylsulfoxide (DMSO).  
Monocytes were pretreated with either DMSO or ethanol solvent alone, c-TUCB (5 M) dissolved 
in DMSO, EETs (100 nM) dissolved in ethanol, or both c-TUCB and EETs for 1 hr before LPS 
stimulation.  The concentration of solvent was always kept below 0.1%.  After pretreatment, 
monocytes were stimulated with LPS (10 ng/mL) for 24 hr at 37 
o
C.  Media was then collected 
and stored at -80 
o
C for later chemokine/cytokine quantification by ELISA.  Media alone and 
monocytes without LPS treatment were used as controls.   
2.2.6 Chemokine/cytokine Quantification by ELISA.   
Media from the tissue culture experiments was assayed for IL-6, MCP-1, macrophage 
inflammatory protein-1 (MIP-1), and TNF- using commercially available ELISA kits (PeproTech, 
Rocky Hill, NJ) in accordance with the manufacturer protocols.  The ELISA detection range for 
IL-6 was 32-2000 pg/mL, MCP-1 was 8-1000 pg/mL, MIP-1 was 16-3000 pg/mL, and TNF- was 
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16-2000 pg/mL.  The measured chemokine/cytokine concentrations produced with each drug 
treatment in the presence of LPS was expressed as a percentage of that seen with treatment of 
LPS alone. 
2.2.7 Cell Immunostaining  





 in 4-well chamber slides (Lab-Tek, Nunc, Rochester, NY) in SFM with 20% 
autologous serum.  After 2 hr, the nonadherent cells were removed by sequential washing with 
PBS.  The adherent cells (majority monocytes) were then fixed in 2% paraformaldehyde (15 min 
at RT), washed with PBS, permeabilized using PBS + 0.1% Triton-x100 + 0.5% BSA (PBST) for 30 
min at RT, and incubated with anti-human-sEH antibody (1:200) alone or in the presence of 
blocking peptide overnight at 4 
o
C.  Primary sEH antibody binding was detected as described 
above for MCP-1 detection except streptavidin Alexa-fluor 546 was carried out at a 1:500 dilution.               
Expression and cellular location of NF-B and phospho-JNK was detected as follows: A 
monocyte-enriched cell population was cultured in SFM with 20% autologous serum for 3 days to 
convert to a macrophage phenotype before removing serum and starving for 48 hr.  The cells 
were then pretreated with vehicle or c-TUCB (5 M) alone for 1 hr. Cells were then exposed to 
LPS (10 ng/mL) for 5, 15 or 45 min then fixed with 2% paraformaldehyde.  Fixed cells were 
immunostained with anti-NF-B (1:100) or phospho-JNK (1:100) using the same antibody binding 
detection procedure described above for sEH. The same experiments were repeated on 
monocyte/macrophages that did not undergo the three day culturing to convert to a complete 
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macrophage phenotype, but were adhered for 2 hr, washed then pretreated with sEHI for 1 hr, and 
exposed to LPS and fixed as described above. 
2.2.8 Foreign Body Giant Cell Detection 
A number of antibodies reported to be specific for macrophages were tested for 
cross-reactivity against porcine macrophages.  No antibody tested was found to be sufficiently 
specific for reliable quantification of macrophages in the paraffin-embedded porcine tissue 
sections.  Foreign body giant cells, which occur in response to frustrated phagocytosis and are 
formed by the fusion of multiple macrophages, were thus used as a measure of macrophage 
recruitment to the vein-graft anastomosis region.  Phosphorylation of inhibitory kappa B (IB) 
releases NF-B for translocation to the nucleus and subsequent transcription of genes involved in 
inflammation. To determine the activation state of the FBGCs, tissue sections were stained with 
anti-phospho-IB.  FBGC accumulation in the AV graft anastomotic regions was assessed by 
visual microscopic inspection of the stained tissue sections and a cell was counted as a FBGC if it 
contained two or more nuclei regardless if it stained positive for phospho-IB.  Four field of views 
(FOV) at 40x magnification were counted in each tissue section and the number of FBGC in the 
four fields of view were averaged.  
2.2.9 Western Immunoblot Analysis for sEH Protein  
The monocyte-enriched cell population was isolated by Ficoll-Hypaque as described above.  
Adherent cells were lysed with RIPA buffer containing a protease inhibitor cocktail (Complete mini, 
Roche Diagnostic, Mannheim, Germany).  The cells were sonicated, soluble lysate collected by 
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centrifugation, and protein concentrations were determined using the bicinchoninic acid (BCA) 
assay (Pierce, Rockford, IL).  Twenty g of lysate were resolved on 4-12% NuPAGE
®
 Bis-Tris 
polyacrylamide gels (Invitrogen).  The resolved protein was then electroblotted onto nitrocellulose 
membranes (Invitrogen, Carlsbad, CA).  Membranes were blocked in 5% nonfat dry milk for 1 hr 
at RT and then incubated with anti-human-sEH antibody (1:2000) alone or in the presence of 
blocking peptide overnight at 4 
o
C.  The antibody binding was detected by incubation with 
anti-rabbit IgG-horseradish peroxidase (HRP) (Santa Cruz Biotechnology) and 
chemiluminescence substrate following manufacturer protocols (Supersignal
®
 West Dura 
Extended Duration Substrate kit, Thermo Scientific, Rockford, IL).  Western blot was quantified 
using densitometry analysis (ImageJ, NIH, Bethesda, MD). 
2.2.10 Cell Harvest and Culture from Wild-type and sEH Knockout Mice  
Procedures and animal care were approved by the Institutional Animal Care and Use 
Committee of the University of Utah.  Wild-type (WT) C57BL/6 mice (Jackson Labs, Sacramento, 
CA) and Ephx2 gene deleted mice (Ephx2-/-) (sEH knockout) were utilized for bone marrow cell 
harvest.  Bone marrow cells (BMCs) were harvested from femurs and tibias of both WT and 
Ephx2-/- mice and differentiated into bone marrow macrophages (BMM) as described previously 
(27, 28).  Briefly, isolated BMCs were plated in BMM media (Dulbecco’s modified Eagle’s 
medium (DMEM, Invitrogen) containing 10% L929 conditioned media, 10% fetal calf serum (FCS), 
1% non-essential amino acids, 1% sodium pyruvate, 1% HEPES, and antibiotic/antimycotics) for 







 in 96 well plates in SFM with 20% FCS.  BMMs were pretreated with c-TUCB, 
EETs, or both, or solvent alone and stimulated with LPS (10 ng/mL) following the same protocol 
mentioned above for human monocytes.  After 24 hr, media was then collected from each well 
and stored at -80 
o
C for later MCP-1 quantification by ELISA.  To serve as controls, media alone 
and BMMs without LPS treatment were used.  
2.2.11 Statistical Analysis  
Data presented for inflammatory cell accumulation was expressed as mean ± SD.  For 
cytokine release studies, cytokine release from cells treated with LPS alone was set as 100% and 
results from other treatments (LPS plus c-TUCB or LPS plus c-TUCB plus EETs) were calculated 
as percent of LPS alone ± SD.  All statistical analyses were performed on the log scale and results 
were exponentiated to express results as ratio of geometric means.  For the human and mouse 
data, LPS plus c-TUCB vs. LPS alone and LPS plus c-TUCB plus EETs vs. LPS alone were the 
two primary comparisons analyzed for each cytokine/chemokine. Mixed effects analysis of 
variance were used, treating the individual or mouse as a random effect and treatment as a fixed 
effect, nesting the individual mouse within the mouse type (WT vs. KO) for the mice data, 
significance was determined using the Holm-Bonferroni procedure for each cytokine/chemokine 
tested in humans and MCP-1 in mice.  For the mice data, cytokine release from LPS alone in WT 
vs. LPS alone in the KO mice and basal cytokine release from untreated WT vs. untreated 





2.3.1 Inflammatory Cells Infiltrate the Vein-graft Anastomosis 
in the Porcine AV Graft Model   
Both CD3+ cells (T lymphocytes) (Figure 2.2B) and foreign body giant cells (FBGC) 
(macrophages) (Figure 2.2C), accumulated at the vein-graft anastomotic region near the graft 
material preceding or in parallel with the accumulation of hyperplasia as indicated in Figure 2.2D. 
The majority of FBGC stained positive for phospho-IB expression (data not shown) as 
determined by visual assessment of multiple tissue sections suggesting activation of 
NF-B.Neutrophil infiltration was observed around the graft sutures within the first week after graft 
placement, but their presence declined rapidly thereafter (data not shown). Sporadic clusters of 
B-lymphocytes were occasionally observed in the hyperplastic tissue at various time points (data 
not shown).  
2.3.2 sEH Expression is Upregulated in the Vein-graft Anastomosis Tissue  
Figure 2.3 shows sEH expression was low in ungrafted porcine external jugular vein, but 
markedly increased over time in tissue collected from the vein-graft anastomosis region in the 
porcine model.  sEH expression was first upregulated in the media of the native vessel of the 












Figure 2.3 sEH expression as assessed by immunohistochemical staining in the porcine model of 
AV graft stenosis. The expression of sEH protein increased in the vein-graft anastomotic tissue 
over time after graft placement (rust color indicates antibody binding; tissue was collected 1 day, 1 
week and 4 weeks after graft placement).  The majority of FBGC (white arrows last frame) stained 

































Figure 2.4. sEH expression in human monocytes.  Confocal images (60x) of 
immunocytofluorescence of human adherent monocytes immunostained with anti-sEH (green) (A) 
alone or (B) in the presence of sEH blocking peptide merged with the fluorescence of the nuclear 
marker, DAPI (blue).  C) Western immunoblot analysis of lysate from human monocytes.  
Blocking peptide decreased sEH staining in both confocal images and western blotting indicating 
staining was specific for sEH.  
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2.3.3 Human Adherent Monocytes Express sEH  
Adherent human monocytes stained strongly for sEH protein in the cytoplasm but also 
somewhat in the nuclei (Figure 2.4A-B) similar to what others have recently reported in rat 
neutrophils, macrophages, and brain cortical astrocytes (29, 30).  Western immunoblotting 
confirmed sEH expression in human monocytes (Figure 2.4C).  Incubating with blocking peptide 
decreased sEH staining as seen by both confocal and western blotting (decreased by ~60% 
determined by densitometry), signifying that staining was specific for sEH. 
2.3.4 Chemokine/cytokine Expression is Upregulated in Porcine Tissue  
TNF- expression, as evaluated by visual assessment of immunohistochemical staining, 
increased after graft placement from a low level at day 1, similar to that seen in control vein, to 
increasing, widespread expression in the hyperplastic tissue out to seven weeks after placement 
(data not shown).  Expression of TNF- was often more intense in FBGC than surrounding tissue 
(Figure 2.5).  Immunofluorescent staining for MCP-1 protein was performed on 
paraffin-embedded tissue from the anastomosis at 1 week, 2 weeks, 3 weeks, and 6 weeks after 
graft placement.  MCP-1 staining in control vein was minimal whereas the vein-graft anastomosis 
tissue had elevated expression of MCP-1 by one week (Figure 2.6) that remained elevated at six 


















Figure 2.5 TNF- expression in hyperplastic tissue of the porcine vein-graft anastomosis. (A) 
Tissue obtained at 2 weeks after graft placement had moderate expression of TNF- (rust color) 
but expression in FBGC (white arrow) was typically enhanced above surrounding tissue.  (B) 
Tissue obtained at 7 weeks after graft placement had high expression of TNF- but expression in 



































Figure 2.6  Immunohistofluorescent staining of MCP-1 in porcine AV graft tissue.  MCP-1 
expression (red) increased at 1 week after graft placement above that seen in control vein, and 
remained elevated at 6 weeks after placement (not shown). The light microscopy images of the 
tissue sections are shown below the fluorescent images. Images were obtained at 20x 




2.3.5 sEH Inhibitor (c-TUCB) Attenuates Chemokine/cytokine  
Release from Human Monocytes   
C-TUCB is a potent and selective inhibitor of sEH (IC50 against recombinant sEH ~0.6 nM) 
(22).  LPS-stimulated MCP-1 and TNF- release from adherent human monocytes was 
significantly inhibited by pretreatment with c-TUCB or c-TUCB plus 14,15-EETs, compared to LPS 
alone (p<0.05) (Figure 2.7A-B).  There was no observable effect on LPS-induced MCP-1 and 
TNF-  release with the addition of 14,15 EETs to the c-TUCB treated cells, or from the addition of 
14,15 EETs alone (data not shown). The addition of 8,9 EETs and 11,12 EETs was also tested but 
neither inhibited MCP-1 or TNF- release when added alone or with c-TUCB (data not shown).  
The secretion of IL-6 (Figure 2.7C) or MIP-1 (Figure 2.7D) after LPS exposure was not inhibited 
by pretreatment with c-TUCB alone or c-TUCB with EETs.  EETs alone had no discernible effect 
(compared to LPS alone) on release of any of the chemokine/cytokines tested (data not shown).  
2.3.6 Response of BMMfrom Wild-type and sEH Knock-out 
Mice to LPS and c-TUCB  
LPS-stimulated release of MCP-1 from WT mouse BMMwas significantly inhibited by 
pre-incubation with c-TUCB (p<0.01) (Figure 2.8), similar to that seen in the human monocyte 
experiments (Figure 2.7).  However, no inhibition was observed when BMMfrom
animals were exposed to LPS after preincubation with c-TUCB (Figure 2.8).  There was no 
discernible effect on LPS-stimulated MCP-1 release with the addition of EETs to c-TUCB-treated 
cells from either WT or KO animals (data not shown).  However, untreated as well as LPS-treated 
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BMM from sEH KO animals had elevated levels of MCP-1 release compared with BMMfrom 
WT animals (untreated: 2162.5 pg/mL  599.4 vs. 1415.6 pg/mL  1010.8; LPS-treated: 6531.2  
5537.4 vs. 2255.7  1424.3; p< 0.009). 
2.3.7 c-TUCB Effects on NF-B Translocation in Human Adherent Monocytes  
EETs have previously been reported to inhibit IB kinase (1, 31), which phosphorylates IB.  
Phosphorylation of IB results in its disassociation from the transcription factor NF-B, allowing 
NF-B to translocate to the nucleus and participate in transcription of genes involved in 
inflammation.  Using a different sEHI than c-TUCB, others have reported inhibition of NF-B  
translocation in cardiomyocytes (31).  We tested the effects of c-TUCB on NF-B translocation in 
human adherent monocytes. NF-B was present in the cytoplasm and nucleus of control 
monocytes as determined by immunofluorescent staining (Figure 2.9). Exposure of cells to LPS 
(10 ng/mL) was associated with NF-B translocation to the nucleus, but preincubation with 
c-TUCB had no marked inhibitory effect on that translocation. No inhibition of NF-B translocation 
was observed at any time point examined or when cells were adhered for either two hrs or three 
days prior to experimentation (data not shown). 
2.3.8 Effect of c-TUCB on JNK in Human Adherent Monocytes  
The activation of JNK, a member of the mitogen activated protein kinase (MAPK) pathway, 
has been reported to be involved in LPS-induced expression of MCP-1 in microglia (32) and 
TNF-induced expression of MCP-1 in astrocytes (33).  EETs have also been reported to inhibit 










Figure 2.7 Effect of c-TUCB on LPS-stimulated release of (A) MCP-1, (B) TNF-, (C) IL-6, or (D) 
MIP-1 from adherent human monocytes. White bars indicate cytokine levels in media alone.  
Cytokine/chemokine release from cells exposed to LPS alone was set as 100% then release that 
occurred with other treatments (c-TUCB plus or minus 14,15 EETs) was expressed as percent of 
that seen with LPS alone. The asterisks denote a statistically significant difference between cells 














Figure 2.8  Release of MCP-1 from LPS-stimulated BMM from wild-type (WT) (white bars) or 
sEH knock-out (KO) (Ephx2-/-) mice (black bars) in the absence or presence of c-TUCB. MCP-1 
release from cells exposed to LPS alone was set as 100% and release that occurred with c-TUCB 
was expressed as percent of that seen with LPS alone. The data shown are from cells collected 
from five mice for both WT and KO mice.  Asterisks denote a statistically significant difference 




monocytes were exposed to LPS, phosphorylation of JNK was enhanced (Figure 2.10).  However 
when cells were exposed to LPS after pretreatment with c-TUCB, phospho-JNK levels were 
markedly decreased, as assessed by immunofluorescent staining (Figure 2.10). 
2.4 Discussion 
We used a validated porcine model to examine the time course for inflammatory cell 
recruitment and sEH expression, within the vascular tissue of synthetic AV grafts.  Others have 
investigated cell phenotypes in human AV graft and fistula vein samples collected during vascular 
revision of stenosed accesses and reported the presence of numerous macrophages (21, 36).  
However, the percentage of grafts that had undergone percutaneous transluminal angioplasty 
prior to revision was unknown, which complicates interpretations since angioplasty itself initiates 
inflammation.  The pool of available human AV graft tissue that has not previously undergone 
angioplasty for treatment of stenosis is small because angioplasty is a first-line treatment for AV 
graft stenosis (37).  The porcine model recapitulates the hyperplasia development that occurs in 
human AV grafts but in a shorter time frame and is a well-accepted large animal model of AV graft 
stenosis (21, 36).  One caveat to this model is the animals are not uremic and uremia may impact 
inflammation.  A porcine chronic renal insufficiency AV graft model has been reported but requires 
28 days to establish uremia prior to graft placement surgery (38).  Up to 6 weeks would further be 
required for advanced stenosis development to occur and the animals would become quite large in 
that time frame and the costs of upkeep would be prohibitive. 







Figure 2.9  Effect of c-TUCB on LPS-stimulated NF-B nuclear translocation in adherent human 
monocytes.  Confocal images of cells immunostained with anti-NF-B (red) (top row) and then 
merged with images of DAPI nuclear stain (blue) (bottom row). NF-B is located primarily in the 
cytoplasm (arrowhead) of cells before exposure to LPS (first column) with little observed in the 
nuclear compartment (arrow). After a 45 min LPS exposure, an increased immunostaining of 
NF-B in the nuclei (arrow) and decreased immunostaining in the cytoplasm (arrowhead) was 
observed (second column).  Pre-exposure to c-TUCB did not inhibit LPS-induced nuclear 
translocation (arrow) (third column).  All images were obtained at 60x magnification. Scale bar is 










Figure 2.10  Effect of c-TUCB on LPS-stimulated phosphorylation of JNK in adherent human 
monocytes.   Confocal images of cells immunostained with anti-phospho-JNK (Phospho-JNK) 
(red) (top row) and then merged with images of DAPI nuclear stain (blue) (bottom row). Low levels 
of cytoplasmic phospho-JNK immunostaining (arrowhead) were observed in untreated cells (first 
column) whereas increased cytoplasmic phospho-JNK immunostaining (arrowhead) was 
observed after 15 min LPS treatment (middle column). Pre-exposure to c-TUCB markedly reduced 
immunostaining of phospho-JNK (red) (last column). All images were obtained at 60x 
magnification.  Scale bar is 30 m.    
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porcine model after AV graft placement.  T lymphocyte accumulation was notable for its early 
appearance and this is the first report to our knowledge on the presence of T cells in AV graft 
tissue.  A previous study reported accumulation of T lymphocytes in thrombosed arteriovenous 
fistulas but in the fistula setting the presence of T cells was likely due to thrombosis and unrelated 
to a foreign body response (39).  T lymphocytes may be influencing the macrophage response to 
the ePTFE graft material.  In support, T cells have been shown in vitro to enhance the adherence 
of macrophages, and the formation of FBGC, on certain synthetic biomaterials (40).  In another 
study, rat aortic smooth muscle cells exposed to conditioned media from human PBMC exposed to 
PTFE had increased proliferation rates compared to smooth muscle cells exposed to conditioned 
media from unexposed PBMC (20).  In vivo studies reported that T-cell-deficient mice had lower 
granulocyte numbers near a variety of subcutaneous biomaterials compared to WT mice (41).  
Also, the mice had lower numbers of adherent macrophages on polyether urethane biomaterial 
implants compared to WT mice.  However, the number of macrophages adhered to other 
biomaterial implants was similar between the two groups.  These data indicate, at least in mice, T 
lymphocyte involvement in macrophage activation is likely material-dependent.  However, the 
precise role that T lymphocytes play in the stenosis of AV grafts is not yet completely known and 
requires further study.  
A number of factors doubtless contribute to the recruitment of inflammatory cells to the AV 
graft including i) the surgical trauma that occurs during graft placement, ii) the bioincompatability of 
the ePTFE graft material and sutures, and iii) the presence of aberrant blood flow that may 
traumatize the vessel wall and also more readily allow inflammatory cell attachment and infiltration.  
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We, and others, have reported the elevated expression of growth factors, cytokines and 
chemokines within the anastomotic tissue of the AV grafts (42-46).  Inflammatory cells are likely 
sources of these factors. Since macrophages and T lymphocytes are early and prevalent 
inhabitants of the AV graft tissue and release cytokines and chemokines that induce migration and 
proliferation, they are attractive targets for pharmacotherapy against AV graft stenosis. 
The hypothesis that sEH may play a role in the marked inflammation observed in AV grafts 
has not previously been investigated. However it is reasonable to posit that sEH may be involved 
since i) the sEH enzyme catabolizes anti-inflammatory EETs and other epoxy fatty acids to the 
less biologically active diols such as DHET, and ii) sEH has been shown to be important in other 
inflammatory conditions.  For example, after middle cerebral artery occlusion, the levels of TNF-, 
IL-6, interferon-gamma and IL-1 mRNA in the brains of sEH KO mice were significantly less 
compared to levels in the brains of WT mice (47).  Also, in animals made hypertensive by 
DOCA-salt treatment, NF-B activity in kidney lysates and MCP-1 levels in urine were significantly 
decreased in sEH knockout mice compared to WT mice (48).  Also MCP-1 protein and NF-B 
activity were decreased in lung homogenates from sEH KO mice compared to WT mice after in 
vivo LPS exposure (49).  Additionally, intraperitoneal injection for two weeks of a dual EET 
agonist/sEHI significantly inhibited plasma levels of TNF- and MCP-1 in heme oxygenase-2 KO 
mice (50). We showed the expression of sEH was markedly upregulated after AV graft creation in 
the vessel wall, first in the medial layer, then in the adventitia and finally the stenotic tissue at the 
anastomosis.  Due to a lack of a sufficiently specific antibody against porcine 
monocyte/macrophages, we were unable to confidently colocalize macrophage identity and sEH 
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immunostaining in our animal model.  However, expression of sEH was detected in ficoll-hypaque 
isolated human peripheral blood monocytes by both immunoblotting and immunocytochemistry.  
Also, FBGCs that are produced by the fusion of multiple macrophages and are readily identified by 
histological analysis, specifically immunostained with anti-sEH antibody suggesting that porcine 
macrophages indeed express sEH.  Subsequently, elevated sEH expression in both the vascular 
tissue and infiltrating inflammatory cells may contribute to inflammation in the AV graft by 
decreasing anti-inflammatory EET levels.  
In this study, we examined the hypothesis that a pharmacological inhibitor of sEH would 
attenuate release of various pro-inflammatory chemokine/cytokines from LPS-stimulated 
monocyte/macrophages.  The hypothesis was proven correct for both MCP-1 and TNF-  To 
confirm that sEHI was attenuating MCP-1 release through a direct effect on sEH, BMMs from 
both WT and sEH KO mice were stimulated with LPS after being pretreated with either sEHI alone, 
EETs alone or both together. Exposure with c-TUCB was associated with decreased MCP-1 
release from LPS-induced WT BMM but not from LPS-induced KO BMM.  If EETs are involved 
in the inhibition of MCP-1 expression, one might expect a decreased basal expression of MCP-1 in 
the sEH KO mice BMM since sEH is not expressed in these animals and their EET levels have 
been reported to be elevated (51).  However MCP-1 release was actually elevated from 
untreated- as well as LPS-stimulated BMM from sEH knockout mice, compared to WT BMM. 
Similarly unexpected findings were reported by Luria et al. who showed that although sEH KO 
mice had elevated plasma levels of 14,15-EET and other cytochrome P450 expoxygenase 
metabolites, they did not have decreased basal blood pressure compared to WT mice (51).  This 
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was surprising since EETs are potent vasodilators (2-4).  However, there were also concomitant 
4-fold increases in production of the potent vasoconstrictor 20-hydroxyeicosatetraenoic acid 
(20-HETE) in the sEH KO mouse kidneys and urine (51).  Of note, sEH KO mice experienced 
markedly less hypotension after an LPS infusion compared to WT mice and their blood pressure 
recovered much more quickly after the LPS insult (51).  It was postulated that the elevated 
20-HETE levels in the sEH KO animals counteracted the hypotensive actions of the elevated 
levels of EETs.  Thus it is possible that other pathways are upregulated in response to sEH 
inhibition in monocyte/macrophage cells similar to what was observed in the whole animal studies.  
Other lipoxygenase metabolites (12- and 15-HETE) are known to induce MCP-1 in murine 
peritoneal macrophages (52).  Levels of 20-HETE or other lipid mediators may be altered in the 
monocyte/macrophages in response to deletion of the sEH pathway resulting in elevated levels of 
MCP-1 but further studies are needed to investigate such possibilities.  Regardless, the 
pharmacological inhibitor of sEH, c-TUCB, inhibited monocyte release of MCP-1 and TNF-. 
The expression of sEH in monocyte/macrophages detected by immunocytochemical and 
immunohistochemical staining is in contrast to a study that reported that human monocytes 
isolated from peripheral blood by column elution had no detectable sEH activity against 
trans-stilbene oxide (53).  That our current study observed i) significant inhibition of MCP-1 and 
TNF- release from monocytes by a selective pharmacological inhibitor of sEH, ii) the sEHI did not 
significantly inhibit MCP-1 release from BMM from sEH KO mice but did in BMM from WT mice, 
and iii) that a blocking peptide specific for sEH markedly decreased anti-sEH antibody binding in 
western immunoblots supports our results that monocyte/macrophages do express sEH.   
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EETs are anti-inflammatory in a number of settings (1, 49). However, the administration of 
exogenous EETs along with sEHI did not significantly augment the inhibitory effects of sEHI, and 
the addition of EETs alone did not significantly alter cytokine release compared to LPS alone.  A 
possible explanation for the lack of effect of EETs alone is that EETs are metabolized to DHETs 
rapidly within the cell before being able to elicit a response (54).  In support of this, the formation 
of the metabolite 14,15 DHET could be detected in the media of cultured porcine aortic smooth 
muscle cells within 3 min after adding 14,15 EETs (54).  However, others have reported effects of 
exogenously applied EETs on cell functions such as cell adhesion molecule expression indicating 
exogenously applied EETs are capable of intracellular effects (1).  Another possibility is that 
albumin, supplemented in the cell culture media in the form of fetal calf serum, reduces uptake of 
EETs enabling rapid hydrolysis to DHETs in the media.  Albumin was shown to decrease the 
uptake of 14,15 EETs by over 50% in mastocytoma cells and increasing the albumin concentration 
reduced uptake even further (55). Also, the exogenously applied EETs could be depleted via 
-oxidation and esterification pathways.                            
MCP-1 (CCL2), a CC chemokine, is a potent chemoattractant that recruits peripheral 
monocytes and memory T-cells into sites of inflammation (56).  Besides monocytes/macrophages, 
many other cell types secrete MCP-1 including T-cells, endothelial cells, smooth muscle cells, and 
fibroblasts (57); all cell types that likely play a role in hyperplasia formation in our porcine AV graft 
model.  Tissue at the vein-graft anastomosis stained positively for MCP-1 at 1, 2, 3, and 6 weeks 
after graft placement showing that MCP-1 production is enhanced and sustained and 
subsequently may be contributing to inflammatory cell recruitment.  Control vein did not express 
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MCP-1.  Increase in MCP-1 expression occurs in other experimental models of neointimal 
hyperplasia.  For instance, upregulation of MCP-1 appeared as early as one day after balloon 
injury in hypercholesterolemic rabbits and was significantly higher than in noninjured control 
vessels, even at 28 days after injury (58).  Also, MCP-1 mRNA levels increased 117-fold in tissue 
one week after epicardial vein-to-femoral artery bypass grafting in rats and remained seven times 
greater than baseline at 8 weeks after grafting (59).  In both cases an increase in inflammatory 
cell infiltration was simultaneously observed. Treatment targeting MCP-1 using either a 
neutralizing antibody for MCP-1 or a plasmid coding for N-terminal deletion mutant MCP-1 was 
effective in inhibiting hyperplasia and macrophage infiltration in a rat carotid injury (60) and a 
mouse or monkey periarterial injury model (61).  Recently, in-stent restenosis in porcine coronary 
arteries was significantly inhibited by oral treatment with bindarit, a selective small molecule 
inhibitor of MCP chemokines (62). Thus, the ability of sEHI to inhibit MCP-1 and TNF- release 
makes it a potential therapeutic for the treatment of neointimal hyperplasia.             
Previous studies have shown that EETs elicit anti-inflammatory effects by inhibiting the 
phosphorylation of IB thereby preventing the activation and subsequent nuclear translocation of 
NF-B. Schmelzer et al. reported that AUDA (another sEHI) decreased IL-6, TNF-, and MCP-5 
plasma levels in LPS-challenged mice and alluded that this effect was derived from the blocking of 
NF-B nuclear translocation (12).  Olearczyk et al. demonstrated that sEHI given in drinking 
water diminished urinary MCP-1 secretion, inhibited NF-B activity and attenuated macrophage 
infiltration into the kidney in hypertensive rats (15).  Others reported that sEH KO mice made 
hypertensive with DOCA-salt, had decreased NF-B activity, decreased urinary MCP-1 and fewer 
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CD68 positive cells in the kidney (48).  In the current study, LPS induced the nuclear translocation 
of NF-B in adherent human monocytes yet pretreatment with sEHI did not inhibit the NF-B 
translocation.  This inability of c-TUCB to inhibit NF-B translocation is consistent with our data 
showing sEHI did not significantly alter IL-6 or MIP-1 release, as NF-B is a key inflammatory 
transcription factor involved in the production of these chemokine/cytokines (63-67). Our data 
indicate that the role of sEH in inflammation is more complex than originally proposed and is likely 
cell specific. 
The enzymes in the MAPK pathway (ERK1/2, p38 and JNK) (68) are also activated by LPS 
exposure (69-72).  Each of these kinases has been reported to participate in MCP-1 and TNF- 
secretion induced by different stimuli in various cell types, and decreased phosphorylation of these 
kinases has been reported to attenuate MCP-1 and TNF- release (73-79).  Elevated EET levels 
were shown to correlate with increased activation of ERK1/2 in endothelial cells (80), and ERK1/2 
and p38 in endothelial cells (81) and macrophages (82).  Potente et al. demonstrated that 
overexpressing CYP2C9 in endothelial cells resulted in increased EET levels and a concomitant 
dephosphorylation of JNK, suggesting that JNK may participate in EET signaling (34).  EETs 
were shown to inhibit JNK activity, and JNK inhibition by dexamethasone suppressed MCP-1 
release in microglia (32), and TNF- release in murine macrophages (83).  We showed that 
levels of phosphorylated JNK were increased after LPS-stimulation in human monocytes, but 
pre-exposure to sEHI almost completely blocked the phosphorylation.  Thus, in human 
monocytes, sEH inhibition likely attenuates MCP-1 and TNF- release via an effect on the JNK 










Figure 2.11  Proposed signaling pathway of how sEHI affects MCP-1 and TNF- release in LPS 
stimulated monocytes.  sEHI binds to sEH which increases the accumulation of EETs that then 
block phosphorylation of JNK, but does not effect the translocation of NF-B.  The effect of EETs 





TNF- release from LPS stimulated macrophages is presented in Figure 2.11.  As multiple 
pathways, such as the NF-B pathway, have been shown by others to be involved in MCP-1 and 
TNF- expression, and such pathways may not be affected by sEH inhibition in monocytes, this 
may explain the lack of complete knockdown of both MCP-1 and TNF- release by c-TUCB. 
2.5 Conclusion 
As discussed above, MCP-1 is a potent chemoattractant and migration stimulus for 
monocytes/macrophages and vascular smooth muscle cells and its high expression level in the AV 
graft anastomotic tissue suggests it may play a role in hyperplasia formation.  This study is the 
first to report that sEHI can inhibit MCP-1 and TNF- release from monocyte/macrophages and 
not through the NF-B pathway, but instead via the JNK pathway (Figure 2.11).  However, as 
expression of other cytokines was not affected, whole animal studies are required to determine 
whether sEHIs will be useful in preventing AV grafts stenosis. 
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A DEGRADABLE PERIVASCULAR WRAP FOR CONTROLLED  
AND DIRECTED DRUG DELIVERY 
3.1 Introduction 
 The pathological overgrowth of cells into the intimal layer of blood vessels is termed 
neointimal hyperplasia (NH).  It is a common problem affecting interpositional vein grafts, arteries 
treated with balloon angioplasty, and catheterized veins, often resulting in stenosis and 
subsequent occlusion.  It is a particularly widespread problem in synthetic arteriovenous (AV) 
grafts used for chronic hemodialysis resulting in the thrombotic occlusion of up to 50% of grafts 
within the first year of placement (1, 2).  Currently there is no effective prevention strategies of 
neointimal hyperplasia associated with AV grafts that are used in routine clinical practice.  
Stenosis typically occurs at the graft-venous anastomosis and is due to the proliferation and 
migration of adventitial myofibroblasts and medial smooth muscle cells (SMCs) to the intimal layer 
(3, 4).  A number of factors likely contribute to NH development, including (i) the presence of the 
synthetic graft material that initiates a foreign body response and (ii) the introduction of arterial 
blood directly into the vein causing flow disturbance and altered wall shear stress.   
The current first-line treatment of AV graft stenosis is percutaneous angioplasty, which has not 
been shown to improve graft survival (5, 6).  Controversy exists as to whether endovascular stent 
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placement after angioplasty provides benefit over angioplasty alone (7).  Haskell et al. reported 
improved restenosis rates with stent placement after angioplasty compared to angioplasty alone, 
but similar thrombotic occlusion rates between the two groups (8).  Systemic pharmacological 
strategies to prevent AV graft stenosis have produced largely disappointing results (9).  A large 
prospective clinical trial testing the efficacy of an oral combination of dipyridamole (an anti-platelet 
agent) and aspirin reported a modest, albeit statistically significant, improvement in one year 
patency rates of the treatment group compared to placebo control (10, 11).  Systemic drug 
administration, especially using anti-thrombotics or anti-neoplastic agents, can result in serious 
systemic toxicities that could be circumvented by localized drug delivery treatment.  Local 
delivery to the stenosis-prone graft-vein anastomosis region would likely achieve much greater 
local drug concentrations with minimal systemic exposure.  As the outer adventitial and medial 
layers are considered to be primary contributors of cells that participate in NH development in AV 
grafts (12, 13), a perivascular approach to drug delivery to inhibit NH is logical.  In a 
proof-of-concept study, we previously reported the inhibition of NH using the perivascular delivery 
of paclitaxel with a polymer gel to the graft-vein anastomosis in a canine model of AV graft stenosis 
(14).  Although the technique inhibited NH, the polymer gel was observed to migrate from the site 
of application.  A wrap would provide a more stationary means of perivascular drug delivery. 
Edelman et al. were the first to report the use of ethylene-vinyl acetate (EVA) polymer wraps 
to deliver heparin perivascularly to rat carotid arteries that sustained luminal injury (15).  
Subsequently, others have used perivascularly applied EVA films to deliver a variety of agents to 
the vasculature, including paclitaxel delivery to injured rat artery (16, 17), growth factor delivery to 
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ischemic rat myocardium (18), and verapamil delivery to a rabbit vein graft (19).  An EVA wrap 
was also used to deliver paclitaxel to the graft-vein anastomosis in a porcine AV graft model and 
was associated with significantly decreased luminal stenosis (20).  As the hemodialysis AV graft 
is subjected to chronic insults such as the thrice weekly puncturing of the graft for dialysis and 
continued presence of uremia, repeat exposure to perivascularly applied drug may be necessary 
to maintain patency over the lifetime of the access.  However, the EVA films are non-degradable, 
thus prohibiting the replenishment of the drug depot, which is likely to be necessary for the 
suppression of NH in a vessel that is under chronic stimulation.  In addition, chronic presence of a 
polymer wrap could initiate a foreign body response.  Film preparations utilizing degradable 
polymers, such as polycaprolactone (PCL) and poly(lactic-co-glycolic acid) (PLGA), may be better 
suited for this application.  In addition to be degradable, both PCL and PLGA are FDA-approved 
for use as suture materials, biocompatible, and can be made into thin flexible sheets suitable for 
an implantable perivascular wrap.  Inhibition of NH was reported with perivascular delivery of 
paclitaxel (21) to a rat carotid artery after balloon injury using a PCL wrap (17), or to a sheep AV 
graft model using a PLGA wrap (22).  However, the PCL wrap was inflexible, making it difficult to 
manipulate and position around the vessel.  A large multicenter clinical trial was initiated to test 
the efficacy of the PLGA-based paclitaxel-eluting wrap for preventing stenosis in AV grafts, but was 
prematurely terminated due to an increased incidence of infection.  Paclitaxel has been reported 
to have inhibitory effects on T lymphocytes in vivo that could diminish the immune system’s ability 
to fight infection (23).  Also, suppression of local immune activity by paclitaxel- or 
sirolimus-eluting stents was suggested to play a role in occurrence of stent infections (24).  Thus, 
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the increased infection incidence was likely a result of paclitaxel not the PLGA wrap.  There is 
need for better degradable platforms for drug delivery to the vasculature. 
The choice of drug to target NH warrants consideration.  Platelet-derived growth factor 
(PDGF) is a potent chemoattractant and mitogen that plays an essential role in initiating SMC 
migration and proliferation (25, 26).  PDGF is not usually expressed in the normal vasculature, 
but upon injury, such as after angioplasty or graft placement, the tissue levels of PDGF and its 
receptors are markedly up-regulated (27-29).  The importance of PDGF in the pathogenesis of 
NH can be illustrated by the attenuation of NH using a polyclonal antibody specific for PDGF in a 
rat arterial injury model (30).  Thus, using pharmacological inhibitors that target PDGF or the 
PDGF receptor family could be a reasonable strategy to inhibit NH development in AV grafts.  
Imatinib, is a tyrosine kinase inhibitor that inhibits both PDGF receptor subtypes and has been 
shown to inhibit restenosis after balloon angioplasty (31).  Sunitinib (Figure 3.1) is a multi-target 
receptor tyrosine kinase inhibitor of both PDGF receptor subtypes, all three VEGF receptor 
subtypes, KIT, FLT3, and CSR-1R; (32) and is currently approved by the FDA to treat 
gastrointestinal stromal tumors and metastatic renal cell carcinoma.  VEGF has also shown to 
contribute to NH by increasing smooth muscle cell activation and neovessel formation at the 
anastomotic region (33).  The ability of sunitinib to inhibit VEGF binding could be beneficial.  The 
therapeutic efficacy of sunitinib in preventing NH formation, however, has not yet been evaluated.  
Data from our laboratory have confirmed the high potency of sunitinib to inhibit PDGF-stimulated 





























shown to restore immunocompetence and enhance immune-dependent chemotherapy against 
leishmaniasis infection in mice (34).   Thus, sunitinib appears to a promising drug for inhibiting 
NH in AV grafts and was utilized in the present proof-of-concept studies.  
We here report the development and characterization of novel degradable, tunable, bilayer, 
wraps using either PCL or PLGA for directed perivascular delivery of sunitinib.  To provide 
unidirectional delivery, a monolithic backing was composed to prevent drug release away from the 
vascular wall and into the extravascular space.  To provide tunability, the drug-laden layer of the 
constructs can be made porous or nonporous and drug can be loaded directly into the PCL or 
PLGA constructs during casting, or drug can be loaded into a hydrogel that is then infused into the 
porous layer.  Since the wrap polymer is degradable, drug can be replenished by injection of drug 
loaded hydrogel to the anastomotic region.  The in vitro release profiles for sunitinib were 
assessed for each wrap formulation.  Additionally, we report the mechanical properties and in 
vivo tissue distribution of sunitinib from a PLGA nonporous bilayer wrap formulation over a 
one-month time course in a porcine model. 
3.2 Materials and Methods 
3.2.1 Materials 
Sunitinib malate (>99% purity) and free-base sunitinib (>99% purity) were purchased from LC 
Laboratories (Woburn, MA).  The internal standard sunitinib-d10 were purchased from Toronto 
Research Chemicals (North York, ON, Canada).  Glycosil (thiolated hyaluronic acid (HA)) and 
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Extralink (polyethylene glycol diacrylate (PEGDA)) were purchased from Glycosan Biosystems 
(Salt Lake City, UT).  Acetonitrile (ACN), methyl-tert-butyl ether (MTBE), ethanol, and acetone 
were of HPLC grade and polycaprolactone (PCL) of various molecular weights (14 kDa - 
polydispersity (PDI) 1.39, 45 kDa - PDI 1.4, and 80 kDa - PDI ~1.6-1.7), were purchased from 
Sigma-Aldrich (St. Louis, MO).  Bovine testicular hyaluronidase (HAse) and other chemicals of 
reagent grade were also obtained from Sigma-Aldrich.  Poly(lactic-co-glycolic acid) (PLGA) (106 
kDa, inherent viscosity 0.65 dL/g) of copolymer ratio 50:50 was acquired from Surmodics 
Pharmaceuticals (Birmingham, AL).  Di-ionized water was prepared with a Millipore Synergy UV 
system (Billerica, MA). 
3.2.2 Preparation of PCL and PLGA Drug-laden and Drug-free Formulations 
Four distinct types of degradable vascular wraps were prepared: (i) nonporous 
sunitinib-loaded PCL monolith, ii) laminated PLGA bilayer of a nonporous sunitinib-loaded film and 
a nonporous unloaded film, (iii) PCL bilayer of a nonporous monolith and a porous monolith, and 
(iv) laminated PLGA bilayer of nonporous film and porous film.  Nonporous formulations (i and ii) 
were loaded with sunitinib during formulation, while porous composites (iii and iv) were loaded with 
sunitinib after fabrication using the HA hydrogel carrier.  Solvent casting and phase inversion 
techniques were used to create all variations of the matrices.  For preparation (i), PCL was 
dissolved at 20% w/v in acetone with stirring at 45
o
C.  Three PCL species were investigated: 45 
kDa, 80 kDa, and a blend of 14 kDa and 80 kDa (at a 2:1 ratio).  Upon complete dissolution of the 
polymer after 60 min, 8% v/v water nonsolvent was added with continued stirring.  After the 
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solution reached homogeneity, sunitinib was added at 0.2% w/w and dispersed with vigorous 
stirring.  The polymer/drug solution was cast into a Pyrex crystallizing dish and permitted to 
degas to the ambient through bubble dissipation with a foil cover.  The dish was placed in a -20
o
C 
freezer overnight to instigate and complete phase inversion of the polymer.  The solvent was 
evaporated from the resulting monolith for 48 hr at room temperature in a chemical fume hood to 
produce the final slab that is suitable for sample punching. 
Preparation (ii) was processed similar to (i) with the following exceptions: a PLGA solution 
concentration of 50% w/v with ethanol was employed as the non-solvent species at 30% v/v. 
Additionally, upon solvent evaporation from the phase inverted system, PLGA collapses to a film, 
instead of maintaining the monolith structure as occurs with PCL.  The film is flexible and can be 
peeled from the evaporative template.  The final bilayer composite was fabricated by lamination 
of the blank films to the drug-loaded films with a small amount of acetone applied with a spray 
bottle.  The bilayer was placed in vacuum at ambient temperature for overnight to eliminate 
residual solvent. 
For preparation (iii), first a layer of nonporous PCL monolith was cast as described in a Pyrex 
crystallization dish, but without loaded drug and solvent evaporation. Identical polymer solution 
mixed with NaCl porogen (>425 µm) to form a slurry was added to the top of the cast monolith and 
allowed to settle. This construct was phase-inverted at -20
o
C and placed in a series of deionized 
water baths for 24 hr to completely extract the porogen and solvent, air dried, and cut to size. 
Preparation (iv) employed the polymer solution described in (ii), but without drug loading and 
slightly different processing than described in (iii) to fabricate the porous bilayer. PLGA solution 
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was mixed with NaCl porogen (>425 µm) to form a slurry in a 50 mL Falcon tube, for a total volume 
of approximately 35 mL. This mixture was centrifuged at 500 rcf for 5 min, after which 15 mL of DI 
water was added to the tube and recentrifuged at the same settings for 30 min to complete system 
phase inversion. The bottom tip of the tube was shaved off and the porogen network was extracted 
in multiple excess DI water baths over 24 hr, ensuring that the tube is upright throughout. The 
resultant porous network was air dried, trimmed to 2 mm and welded to a placard of preparation (ii) 
using a small amount of acetone applied with a spray bottle. Samples were solvent evacuated in a 
chemical fume hood and punched to sample size. 
3.2.3 Scanning Electron Microscopy (SEM) Imaging  
SEM was performed on representative sample cross-sections and surfaces of each polymer 
matrix. After gold deposition, samples were imaged on a Hitachi S3000-N model instrument, PCL 
matrices at 3 kV and PLGA at 10 kV. 
3.2.4 In Vitro Drug Release Experiments 
In vitro drug release studies were performed using polymer constructs with the sunitinib 
incorporated into either the bulk polymer material or the impregnated hydrogel.  For drug release 
experiments from monolithic drug-laden PCL samples, 250 L of each MW PCL or the PCL blend 
was cast into 1.5 mL Eppendorf tubes then processed as described.  Drug release was also 
tested from (i) a drug-loaded porous PCL layer welded to a drug-free nonporous PCL layer, (ii) a 
drug-loaded nonporous PLGA layer welded to a drug-free nonporous PLGA layer, or (iii) a 
drug-loaded porous PLGA layer welded to a drug-free nonporous PLGA layer.  Uniform samples 
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of monolithic PCL and bilayer PLGA polymer constructs were created using a 10-mm biopsy punch.  
For the bilayer PCL constructs, strips (2 x 0.5 x 0.6 cm) were used.  
Drug-release studies were also performed using porous/nonporous bilayer polymer 
constructs infused with Glycosil hydrogel.  Briefly, 1% w/v hydrogel solution was dissolved in 
deionized H2O, then crosslinked with 2% (w/v) Extralink in deionized H2O at a volume ratio of 4:1 
following manufacturer instructions.  Sunitinib or sunitinib free-base powder was added prior to 
crosslinking of the hydrogel (5 mg drug/mL hydrogel in the PCL constructs; 3 mg drug/mL hydrogel 
in the PLGA constructs).  Directly after addition of the crosslinking agent and prior to gelling, the 
hydrogel was infused into the porous layer of the polymer constructs by applying the hydrogel to 
the surface of the porous layer, then placing the constructs under vacuum.  The hydrogel was 
then allowed to gel overnight.  To examine the effect of porous PCL without hydrogel on drug 
release, dry sunitinib free base was vacuum pulled into the porous PCL without hydrogel.  
For drug release kinetics, the polymer constructs were placed in 20-mL borosilicate 
scintillation vials covered with 5 mL of release medium, which was comprised of 1x PBS with 2% 
bovine serum albumin (BSA), then incubated in a water bath at 37
o
C with gentle shaking.  
Release medium was removed daily for testing and replaced with an equal volume of fresh 
medium. 
The release profile of free base sunitinib from hydrogel alone (no polymer construct) in the 
presence or absence of hyaluronidase (5 mU/mL), a concentration similar to that found at wound 
sites (35), was also examined.  All in vitro release experiments were completed in triplicate and 
the cumulative release was expressed as the mean (± SD) percentage of the original loaded mass.  
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The final concentration of all samples was 5 mg of sunitinib per mL of hydrogel.  Directly after 
addition of the crosslinker, the drug-loaded hydrogel samples (0.4 mL) were placed in the bottom 
of 20-mL borosilicate scintillation vials and allowed to fully crosslink overnight.  In the experiment 
incorporating HAse into the release medium, HAse-containing medium was made fresh daily.   
One milliliter of release media samples were spiked with internal standard (sunitinib-d10).  
Drug was extracted from the release media by vortexing with MTBE (4 mL) for 2 min in 16 x 100 
mm screw-capped borosilicate test tubes.  The tubes were centrifuged at 25 
o
C at 2000xg for 15 
min.  The organic layer was collected and solvent evaporated at 42 
o
C overnight.  Dried samples 
were reconstituted in 200 L of 65:35 ACN:H2O containing 0.1% formic acid and injected into the 
HPLC MS/MS system and sunitinib concentrations were determined using the HPLC MS/MS 
protocol described below. 
3.2.5 Unidirectional Transport Studies with PCL and PLGA Monolithic Backing 
PCL and PLGA monoliths (1 mm thickness) were cast without porogen as described above. 
Uniform discs were cut from the polymer monoliths with an 8-mm biopsy punch.  Costar 
Transwell
®
 cell culture inserts (Corning, Corning, NY) were modified as follows.  The 
polycarbonate insert membranes were replaced with either the PCL or PLGA discs.  Discs were 
affixed into the insert position using ethyl cyanoacrylate adhesive.  For the PCL study, solid 
sunitinib free base was mixed with hydrogel (8 mg/mL) prior to crosslinking and 50 L of the 
hydrogel/drug mixture was applied on top of the PCL disc.  Then 100 L of release media was 
added above the hydrogel.  For the PLGA study, sunitinib malate was dissolved in the release 
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media (200 g/mL) and 125 L was added above the PLGA discs.  For visual tracking of solute 
traffic, Oil Red O (a hydrophobic dye) was dissolved in release media instead of drug, and 125 L 
of the mixture was added above the polymer discs.  The inserts were placed into 24-well plates 
with 1.2 mL release media in the bottom of the well.  The plates were incubated at 37
o
C for 72 hr 
to allow for possible drug/dye diffusion through the polymer membrane.  After 72 hr, a sample of 
the media above the polymer discs and a sample below the discs were collected.  Oil Red O 
content in the media was quantitated by absorbance at 521 nm using the NanoDrop 2000 
spectrophotometer (Thermo Scientific, Waltham, MA) and sunitinib concentrations were quantified 
using the HPLC MS/MS protocol described below. 
3.2.5 Mechanical Testing 
PLGA constructs with and without sunitinib were cut into dog-bone shapes (2 cm x 3.5 mm in 
the middle at the breakpoint; 0.5 mm thickness).  The effect of hydration on the elasticity of the 
PLGA samples with and without drug was analyzed after immersing the samples in PBS at 37
o
C at 
various durations (0 days, 1 day, and 7 days).  The samples were then subjected to tensile testing 
using an Instron 4465 (Instron Corp., Norwood, MA) at a speed of 1 cm-min
-1
 for all samples 
except for the 7-days -non-drug-loaded PLGA constructs that were assessed at 1 mm-min
-1
.  
Force was measured as a function of the elongation until breakage of the sample.  Young’s 
modulus of elasticity, a measure of elasticity, was calculated by the Instron from the slope of the 
initial linear section of the stress strain curve.  Five repetitions for each sample treatment were 
performed.   
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3.2.6 Polymer Constructs for Animal Experiments 
PLGA bilayer constructs were created following the method described above.  In short, a 
PLGA monolith backing (3 cm x 3 cm) was solvent-welded to (i) a drug-loaded (sunitinib malate 
(0.1% w/w, 143±5.5 g drug)) monolithic PLGA layer (3 cm x 2.5 cm), or (ii) drug-free PLGA 
monolithic layer (control wrap).  The wraps were sterilized using a STERRAD
®
 system (ASP, 
Irvine, CA) that uses low-temperature hydrogen peroxide gas plasma.  
3.2.7 Surgical Procedures 
All animal work was performed using protocols approved by the Institutional Animal Care and 
Use Committee of the University of Utah and Veterans Affairs Salt Lake City Healthcare System 
and followed guidelines specified by the Guidelines for the Care and Use of Laboratory Animals. 
A porcine model was utilized for perivascular wrap testing.  Briefly, three-month old Yorkshire 
cross-domestic swine (~30 kg) were anesthetized using a mixture of ketamine (4 mg/kg; Hospira 
Inc., Lake Forest, IL), xylazine (4 mg/kg; Lloyd Laboratories, Shenandoah, IA), and 
tiletamine/zolazepam (4 mg/kg; Fort Dodge Animal Health, Fort Dodge, IA).  To maintain 
anesthesia, 1-3% isoflurane was administered via tracheal intubation.  Under sterile conditions, 
bilateral external jugular veins were dissected.  The adventitial layer was removed from the 
external jugular veins to elicit an injury response.  A sunitinib-loaded perivascular wrap was 
placed around the external jugular vein on one side and a control wrap was placed on the 
contralateral external jugular vein in each pig.  To seal the wrap edge, Loctite (Westlake, OH) 
medical grade adhesive was applied along the length of the wrap edge.  Two sutures were placed 
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at either end of the wrap.  The surgical wounds were closed.  Post-operatively, the surgical 
wounds were assessed daily for adverse effects such as bleeding, swelling and infection.  In the 
first animal, in order to increase the amount of tissue pharmacokinetic data obtained, a 
drug-loaded wrap and a contralateral drug-free wrap were also placed around the femoral veins in 
the upper hind limbs in addition to the wraps placed in the neck.  However, swelling occurred in 
the operated hind limbs that required draining, although the swelling did not affect the animal’s 
mobility.  Nonetheless, because of the swelling, polymer wraps were placed in the neck region 
and not in the femoral areas.  Blood was drawn weekly to detect sunitinib in the peripheral 
circulation.   
3.2.8 In Vivo Drug Distribution in Tissues 
The external jugular veins and surrounding tissues from the porcine model were 
collected at one, two, and four weeks after wrap placement and processed immediately after 
explantation.  The tissue from one animal was used for each time point.  A 0.5-cm segment of 
the wrapped veins was formalin-fixed and paraffin-embedded for histological assessment.  The 
remaining length of the wrapped vein was processed for drug detection.  Briefly, fibrous tissue 
and wrap that surounded the vein was removed separately and retained for drug extraction.  The 
vein tissue was isolated and retained for drug extraction in a similar manner.  Sections of the vein 
that were proximal and distal to the wrapped vein segment were also isolated separately for drug 
extraction.  The ipsilateral stenocleidomastoid muscle adjacent to the vein was removed from the 
drug-treated side and separated into six segments.  Lateral tissue adjacent to the veins was also 
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isolated.  The position and weight of each tissue section were recorded.          
Tissue segments were homogenized in 1X PBS (PowerGen 700, Fisher Scientific, Pittsburgh, 
PA) for 1 min.  To monitor the drug recovery during tissue extraction, 200 L of sunitinib-d10 
(internal standard solution at 500 ng/mL) in running buffer was added to 0.5 mL of tissue 
homogenate.  The extraction procedure was the same as previously described for extracting 
sunitinib from the release media, but was repeated once more by adding 100 L of 0.05 N NH4OH 
and 4 mL TBME to the aqueous layer.  The two collected organic fractions were then combined 
and evaporated to dryness at 42
o
C overnight.  Samples were reconstituted in 200 L of 65:35 
ACN:H2O running buffer containing 0.1% formic acid and 10 L was injected into the HPLC 
MS/MS system.  The concentrations of sunitinib were determined using the HPLC MS/MS 
protocol described below. 
3.2.9 Sample Analysis by HPLC Tandem Mass Spectrometry  
The sample analysis protocol was modified and adapted from previously published protocols 
(36-38).  The analytical separation of sunitinib and sunitinib-d10 internal standard were 
performed using an Atlantis dC18 column (2.1 x 30 mm, 3.0 m) (Waters Corp., Milford, MA), 
protected by a 4 mm x 2 mm C18 packed guard column (Phenomenex) at 25
o
C on an Acquity 2695 
HPLC system (Waters Corp.) or on an Acquity UPLC H-Class system (Waters Corp.), both 
equipped with a refrigerated autosampler.  The mobile phase consisted of acetonitrile-deionized 
H2O (65:35, v/v) containing 0.1% formic acid and was run isocratically at a flow rate of 0.3 mL/min.  
Sample run times were 6 min on the Acquity 2695 HPLC and 4 min on the Acquity UPLC H-Class 
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and were followed by a 2-min needle wash to prevent possible carryover.  The internal standard 
and the sunitinib extracted from the samples eluted at 1.2 min on the Acquity 2695 HPLC.  For 
the Acquity UPLC H-Class the internal standard an sunitinibeluted at 0.42 min.     
Two independent triple quadropole tandem mass spectrometers (Micromass® Quattro II or 
Acquity TQD, Waters Corp.) equipped with an electrospray ionization (ESI) interface were used for 
analytical detection.  The Micromass
®
 Quattro II was coupled with the Acquity 2695 HPLC system, 
while the Acquity TQD was coupled with the Acquity UPLC H-Class system.  For the Micromass
®
 
Quattro II, quantification was performed in positive-ion mode using multiple reaction monitoring 
(MRM) of the transition masses of sunitinib (m/z 399.4 → 283) and the sunitinib-D10 internal 
standard (m/z 409.3 → 283).  Instrument parameters were optimized for simultaneous detection 
of both sunitinib and the internal standard.  The capillary energy was set at 3.50 kV, cone voltage 
at 35 V, extractor at 3 V, source block temperature at 125
o
C, desolvation temperature at 325
o
C, 
and the optimal collision energy was determined to be 18 V.  Calibration curves for both sunitinib 
and internal standard were established using standard samples at 11 concentrations ranging from 
4 ng/mL to 500 ng/mL.  The coefficient of determination (r
2
) from a least squares linear regression 
was 0.999 for sunitinib and 0.998 for the internal standard.  The lower limit of quantification 
(LLOQ) was 4 ng/mL for both sunitinib and sunitinib-D10.    
For the Acquity TQD, quantification was performed in positive-ion mode using multiple 
reaction monitoring (MRM) of the transition masses of sunitinib (m/z 399.4 → 283.1) and 
sunitinib-D10 (m/z 409.4 → 283.1).  Instrument parameters were optimized for simultaneous 
detection of both.  The capillary energy was set at 1 kV, cone voltage at 35 V, extractor at 4 V, 
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source block temp at 100 
o
C, desolvation temperature at 250 
o
C, and the optimal collision energy 
was 35 V.  Calibration curves for sunitinib and sunitinib-D10 were established using standard 
samples at seven concentrations ranging from 6 ng/mL to 500 ng/mL.  The coefficient of 
determination (r
2
) from a least squares linear regression was 0.999 for sunitinib and 0.999 for 
sunitinib-D10.  The LLOQ was 3 ng/mL for sunitinib and sunitinib-D10.  
Validation of the HPLC MS/MS method was performed using spiked samples of release 
media, plasma, and tissue for accuracy and precision.  Sample recovery >90% was attained for 
sunitinib, as determined by percent recovery of the internal standard. 
3.2.10 Data Analysis 
Linear regression for calibration curves, graphing, and statistical calculations for comparing 
sunitinib in vitro release from various MW monolithic PCL were performed using Graphpad Prism
®
 
software (La Jolla, CA).                
Cumulative release data from each formulation tested were fitted by nonlinear curve fitting 
using Graphpad Prism
®
 software.  For all formulations tested except for sunitinib free base out of 
the hydrogel and nonporous bilayer PLGA construct, cumulative release was fitted using 
one-phase exponential association.  A linear fit (indicating zero order release) was used to fit 
release of sunitinib free base from the hydrogel.   Drug release from the nonporous PLGA 
construct demonstrated a two-phase release mechanism, consisting initially of diffusion out of the 
matrix followed by a rapid release of drug due to bulk degradation of the PLGA matrix (which 
dominates release in this phase) and diffusion.  A two-phase model that was modified by Duvvuri 
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et al. (39) to describe the release of ganciclovir from PLGA microspheres was used to fit the 
release data.  The following equation was applied (1): 
 
 
           
where F is the fraction of total drug released over the entire observation period; A is the 
percentage of total drug released during phase I; K1 is the rate constant of drug release in phase I; 
B is the percentage of drug released during phase II; K2 is the drug release rate constant during 
phase II; and T50 is the time taken to release 50% of the loaded drug.  Release parameters 
obtained from the curve fit of this equation: A was 30%, K1 was 0.081 day
-1
, B was 76.4%, K2 was 
0.65 day
-1
, and T50 was 33.1 days.  Rate constants for each formulation were derived from the 
curve fitting and were used to calculate the t1/2 of drug release for each phase if more than one. 
3.3 Results 
3.3.1 Physical Characteristics of PCL and PLGA Perivascular Wrap Formulations 
As shown in Figure 3.2, small pores were visible in the PCL monolith surface even in the 
absence of a porogen during casting (Figure 3.2A).  In contrast, in the PLGA film, a solid layer 
(Figure 3.2B) was observed with no notable porosity.  Large-pore PLGA and PCL constructs were 
prepared by incorporating NaCl as a porogen during the casting process.  The porous PCL 













Figure 3.2 Morphology of PCL (A,C) and PLGA (B,D) polymer constructs formed in the absence 
(A, B) or presence (C,D) of porogen as determined by SEM.  
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intervening material (Figure 3.2C), whereas the porous PLGA construct contains the large pores 
formed by the NaCl porogen but the intervening material is nonporous (Figure 3.2D).  In 
subsequent text the term “porous” describes the constructs created with the porogen.  For 
simplicity, “nonporous” will be used to describe the constructs created in the absence of porogen, 
although PCL constructs formed in the absence of porogen contain micropores. 
Bilayer wrap formulations for unidirectional drug delivery were created by laminating a 
drug-free construct, to serve as a blockade to extravascular drug release, onto another 
drug-loaded construct to serve as a drug reservoir for sustained release to the blood vessel wall.  
Images of the constructs are shown in Figure 3.3.  With PLGA, the drug-loaded layer was either a 
porous (middle column) or a nonporous (far right column) construct. The porous layer was infused 
with sunitinib-loaded hydrogel.  As sunitinib is bright yellow, infusion of the drug-laden hydrogel 
imparted color to the porous PLGA layer.  PLGA cast in the absence of a porogen was amber 
colored even though no drug was present (nonporous layer, first column). With the bilayer PCL 
construct, the top layer cast with porogen and the bottom layer cast without porogen were both 
white (first column).  When the porous layer was infused with sunitinib-containing hydrogel, both 
layers became yellow.  The nonporous layer absorbed drug from the porous hydrogel-infused 
layer, likely because even in the absence of porogen, the PCL monolith contains micropores 
(Figure 3.2).  In light of this contamination of the lower nonporous monolith with drug, a PCL 







Figure 3.3  PCL and PLGA constructs. PCL constructs are shown in the first row.  The first 
column shows a “porous/nonporous” bilayer construct created without drug.  The second column 
shows the same construct as the first except drug-laden hydrogel was infused into the porous 
layer.  The drug (sunitinib) is bright yellow.  Note the nonporous PCL layer is yellow as it has 
absorbed some of the drug-laden hydrogel likely because of the micropores present in that layer.  
The third column shows a monolayer nonporous construct containing drug that was added during 
casting.  No drug-free nonporous layer was present in this construct.  PLGA constructs are 
shown in the second row.  Bilayer PLGA constructs were formed by laminating a PLGA layer 
formed in the presence of a porogen during casting, on to a PLGA layer formed without addition of 
a porogen during casting.  The image in the first column shows the “porous/nonporous” bilayer 
construct formed without drug in either layer. The PLGA polymer appears amber when formed 
without a porogen even in the absence of drug.  The image in the second column shows the 
same construct as the first except drug-laden hydrogel was infused into the porous layer.  The 







3.3.2 Testing PCL or PLGA Bilayer Constructs for Unidirectional Solute Release 
The foundational PCL or PLGA backing formed in the absence of porogen was expected to 
curtail release of drug or solute to the extravascular space.  To test this, a modified transwell 
system was created where discs of the PCL or PLGA nonporous constructs were substituted for 
the cell culture insert.  The discs served to separate an upper and a lower media chamber.  
Sunitinib-laden hydrogel was placed in the upper chamber above the PCL discs.  Sunitinib 
dissolved in media was placed in the upper chamber above the PLGA discs.  Oil Red O, a 
hydrophobic dye with a molecular weight similar to sunitinib, was also used, except the dye was 
dissolved in media in the upper chambers above either PCL or PLGA discs.  As shown in Figure 
3.4, a very small amount of drug was detected in media collected at 72 h from the lower chamber 
below the PCL insert (~0.01% of the amount of drug detected in the upper chamber).  However, 
no drug was detectable in the lower chamber beneath the PLGA insert. Oil Red O levels were 
below detection in the lower chamber beneath either PLGA or PCL inserts. 
3.3.3 In Vitro Drug Release Profile from Hydrogel 
Both the salt form of suntinib (sunitinib malate) and the free base (FB) form were used for 
drug release studies.  Either drug form was mixed with hydrogel prior to gel crosslinking.  
Sunitinib malate readily dissolved into the hydrogel whereas the sunitinib FB remained in 
particulate form within the matrix.  The cumulative release profiles of either form of sunitinib are 
shown in Figure 3.5.  Almost complete release of sunitinib malate was observed from the 





Figure 3.4. A) Unidirectional release study using monolithic PCL as an insert to separate upper 
and lower media chambers.  Sunitinib free base was added to hydrogel that was then placed in 
the upper chamber on top of the PCL monolith.  After 72 hr, the media was collected from the top 
(T) and bottom (B) chambers and analyzed by HPLC/MS/MS for presence of drug.  Oil Red O 
was dissolved in media and placed in the upper chamber.  After 72 hr, the media was similarly 
collected and analyzed by UV/Vis for absorbance at 521 nm.  B) Unidirectional release study 
using monolithic PLGA as the separating insert.  Sunitinib malate or Oil Red O was dissolved in 
media that was placed in the upper chamber above the PLGA monoliths.  Media was collected 
from the top (T) and bottom (B) chambers and analyzed similar to the PCL experiments.  Media in 

















Figure 3.5. In vitro release profile of drug from hydrogel.  Sunitinib malate (solid circles), sunitinib 
free base (FB) (diamonds), and sunitinib FB in the presence of hyaluronidase (HAse) (5mU/mL) 
(triangles).  




































release occurring by day 15 and 100% release occurring between 24 and 30 days, at which point 
the hydrogel had hydrolyzed completely. Table 3.1 shows the half-lives (t1/2) and release constant 
(k) values for release of either form of sunitinib from the hydrogel. With the addition of HAse, an 
enzyme present in wound tissue that breaks down the major hydrogel component, hyaluronate, 
the drug release curve had a steeper incline in the first five days indicating enhanced release of 
drug in that time period. However, complete release of drug in the presence of HAse occurred by 
24 days, which is similar to that seen in the absence of HAse, suggesting that the hydrolysis of 
hydrogel over enzymatic cleavage may be the more important factor in hydrogel breakdown. The 
free base form of sunitinib underwent a much slower release from hydrogel.  Sunitinib FB was 
also able to inhibit PDGF-induced smooth muscle cell proliferation (IC50 ~ 17 nM).   
3.3.4 In Vitro Drug Release Profiles from PCL Formulations      
Sunitinib FB was mixed with hydrogel then infused under vacuum into the porous layer of a 
porous/nonporous PCL bilayer construct. Compared to what was observed previously with 
sunitinib FB release from hydrogel alone (Figure 3.6 diamonds), a slower release of drug was 
observed from sunitinib FB-loaded hydrogel infused into the PCL constructs (Figure 3.6) solid 
circle). Eighty percent of drug was released from the PCL construct by 50 days at which time the 
study was terminated.  When sunitinib was loaded into the porous PCL layer, without hydrogel, a 
large burst of drug release was observed in the first 10 days (~67% release) followed by a slower 
constant release to 35 days (Figure 3.6).  The rapid initial release of drug was likely due to drug 











Table 3.1 Summary of release constants (k) and half-lives (t1/2) for each polymer construct 
 
Delivery system k or k1 t1/2 
(days) 
k2 t1/2  
(days) 




Sunitinib from 45 kDa PCL 0.30 2.28 -  0.952 
Sunitinib from 14/80 blend PCL 0.29 2.38 -  0.993 
Sunitinib FB from hydrogel in 
porous bilayer PLGA 
0.21 3.27 -  0.937 
Sunitinib from 80 kDa PCL 0.15 4.61 -  0.878 
Sunitinib FB from porous PCL (no 
hydrogel) 
0.12 5.77 -  0.916 
Sunitinib FB from hydrogel in 
presence of HAse 
0.086 8.05 -  0.976 
Sunitinib from nonporous bilayer 
PLGA 
0.081 8.56 0.65 1.06 0.982 
Sunitinib FB from hydrogel in 
porous PCL 
0.031 22.26 -  0.993 





”sunitinib” indicates sunitinib malate 
FB = free base 














Figure 3.6 In vitro release profiles of sunitinib free base (FB) loaded into porous PCL  (no 
hydrogel) (diamonds), sunitinib FB loaded in hydrogel then infused into porous PCL (solid circles), 
and sunitinib FB loaded into hydrogel alone (no polymer construct) (triangles).  








Sunitinib FB from hydrogel alone
Sunitinib FB from hydrogel infused into
PCL



























PCL material.  The half-lives and release constants are again shown in Table 3.1.  Incorporating 
drug-laden hydrogel into porous PCL prolonged the release of sunitinib and allowed for more 
consistent release out of the matrix (compare in Figure 3.6 the broad standard deviations 
observed in drug release from PCL alone (no hydrogel) with tight standard deviations in drug 
release from hydrogel-infused PCL).   
The previous experiments used 80 kDa PCL for construct formation.  The 80 kDa PCL can 
resist in vivo degradation and remain intact within the body for over eighteen months (40).  Our 
previous report showed that perivascular injections of drug-laden hydrogels to the anastomotic 
region could provide effective inhibitory concentrations of drug (14, 41).  As hemodialysis grafts 
are subjected to continued pro-hyperplasia insults such as repeated puncturing by dialysis needles 
and the uremic milieu, later perivascular drug application may be needed after drug depletion 
occurs from a perivascular wrap.  Thus attempts were made to create PCL-based constructs with 
faster degradation profiles that retained mechanical characteristics useful for wrapping vessels.  
Such a wrap could be placed at the anastomosis directly after AV graft creation to maintain drug at 
the region for a specific period but this treatment could be followed by perivascular injection of 
drug at later time points if needed.  Nonporous constructs made from lower molecular weight PCL 
or blends of PCL were tested.  Sunitinib was loaded into PCL constructs formed using either 45 
kDa, 80 kDa, or a blend of two-thirds 80 kDa and one third 14 kDa molecular weight PCL.  For 
these experiments, the constructs did not have the monolithic backing. The three molecular weight 
preparations of PCL demonstrated an initial rapid drug release within the first seven days followed 
by a slower continuous release (data shown in Figure 3.7).  All drug was released from both the 
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lower molecular weight construct and blend construct around day 10.  The initial burst of sunitinib 
was greater in the first ten days from the 45 kDa and 14/80 kDa blend PCL than from the 80 kDa 
PCL.  The release constants are shown in Table 3.1.  Attempts to form constructs from 14 kDa 
PCL failed as the polymer had little mechanical integrity and readily crumbled after thermal phase 
inversion. 
3.3.5 In Vitro Drug Release Profile from PLGA Formulations      
PLGA is degradable and degradation rates can be modified based on the ratio of lactide to 
glycolide (42) making this polymer an attractive option for vascular wrap development.  Release 
of sunitinib was tested from two PLGA bilayer wrap formulations, a porous/nonporous bilayer 
construct and a nonporous/nonporous bilayer construct.  Drug release from hydrogel loaded with 
sunitinib FB infused into the porous layer of the porous/nonporous PLGA construct was complete 
by approximately 15 days (Figure 3.8).  When sunitinib was loaded into a nonporous layer of a 
nonporous/nonporous bilayer PLGA construct, complete drug release did not occur until 
approximately 35 days.  The release occurred in a biphasic fashion with an initial slow release 
until 30 days whereupon a rapid release occurred.  This construct initially provided a steady 
release of drug, similar to commercially available drug-eluting stents.  The rapid release was 
accompanied by physical degradation of the construct as determined by visual assessment.   
Release constants (k) and half lives (t½) for drug release from each polymer construct.  The 
release constant (k) and the half life (t1/2) for drug release from each polymer construct were 













Figure 3.7 In vitro release profile of sunitinib from different molecular weight nonporous unilayer 










Figure 3.8 In vitro release profile of sunitinib malate from PLGA construct consisting of a 
drug-loaded nonporous/drug-free nonporous bilayer (triangles), or PLGA construct consisting of a 
sunitinib FB-loaded hydrogel infused into a porous/nonporous bilayer (circles). 
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release profiles can be accomplished by not only the use of different polymers for construct 
formation but also by modifying the porosity, the molecular weight of the polymers and also by 
combining hydrogels with polymers.  In the instance of drug release from the nonporous bilayer 
PLGA construct, a biphasic release profile was observed and one release constant for each phase 
is shown.  Drug release from the porous 80kDa PCL construct infused with drug-loaded hydrogel 
had the longest t1/2.  However, the 80kDa construct is predicted to have a very long life in vivo 
based on other reports. 
3.3.6.In Vivo Drug Distribution in Porcine Tissue 
Sterile PLGA bilayer constructs (sunitinib-loaded nonporous layer/drug-free nonporous layer) 
of 3 cm x 3 cm x 1 mm dimensions were placed around the external jugular vein (EJV) in swine.  
Drug-free bilayer constructs were placed on the contralateral EJV.  After placement, the wounds 
were sutured and the animals were survived for 1, 2 or 4 weeks (one animal each time point) 
whereupon they were euthanized and the EJV and surrounding tissues were explanted for 
histology and drug detection.  The wounds were evaluated weekly and no infections or 
remarkable swellings or delays in wound healing in the neck area were noted in any animals.  
However, in the first animal that was maintained for 4 weeks, we additionally placed a drug-loaded 
wrap and a drug-free wrap around the femoral veins in the upper hind limbs.  In this location the 
femoral veins are very close to the surface with little surrounding tissue to compress the region.  
In addition the femoral veins have numerous branches that required ligation prior to wrap 
placement.  Due to such factors, noteworthy amounts of edema formed in the hind limbs that 
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required draining.  Thus wraps were not placed around the femoral veins in subsequent animals 
and the drug’s pharmacokinetics was not analyzed in the tissue of those regions.  Although 
edema formed in the hind limbs in the one animal that received wraps in that area, the wraps in the 
neck region were always well tolerated. 
At explant, no signs of infection or serous fluid near the wraps in the neck were observed at 
any time point.  After 1 week, the PLGA wrap remained intact as determined by visual 
assessment after explant (Figure 3.9).  At 2 weeks, the wrap appeared to be degrading and 
becoming incorporated with tissue.  At 4 weeks, the wrap was only visually detectable as small 
flakes of material that had become incorporated with fibrous tissue.  It was observed that the 
wrap material was quite stiff at explant at every time point whereas the wraps were flexible prior to 
implant.   
Distribution of sunitinib into the EJV wall, any surrounding fibrous tissue, the 
sternocleidomastoid muscle, and tissue adjacent to the vein, was assessed as illustrated in Figure 
3.10.  At 2 weeks, drug concentration more than doubled in the wrapped vein segment compared 
to the amount present at one week and remained elevated even at 4 weeks when the wrap had 
degraded considerably.  Sunitinib concentrations detected in the wrapped portion of the EJV at all 
three time points were much greater than the experimentally determined IC50 needed to inhibit 
proliferation of PDGF-stimulated smooth muscle cells. 
Drug was detected in the EJV at 2 cm proximal of where the wrap was placed at one week, 
but was at least four times less than seen in the wrapped vein area.  At 2 weeks and 4 weeks 














Figure 3.9 Drug-laden PLGA bilayer perivascular wraps in a porcine model. Panel A) Upper 
picture: The dissected porcine external jugular vein (EJV) just prior to wrap placement.  Lower 
picture: A sunitinib-loaded PLGA bilayer wrap placed around the EJV.  Panel B)  Drug-loaded 
wraps imaged in situ after dissection at 1, 2, or 4 weeks after placement in vivo. Cross-sectional 







much less than in the wrapped vein (Figure 3.10).  Sunitinib was undetectable at the three time 
points in the distal portion of wrapped vein segments, tissue adjacent to the vein, and in all tissue 
sections on the control side.  Blood was drawn weekly from each pig until euthanasia and 
systemic concentrations were undetectable except at four weeks after wrap placement wherein 
3.6 ng/mL was detected.  The animal with detectable systemic concentrations of drug was the 
animal that had received two drug-laden wraps, one in the hind-limb and one in the neck.  Thus 
the contribution of the wrap in the hind-limb to systemic concentrations could not be separated 
from the contribution of the wrap in the neck.  However, as there was significant fluid 
accumulation in the hind-limb area, this wrap may have contributed more to the systemic 
circulation. 
The remaining wrap and any incorporated fibrous tissue was removed at each time point and 
analyzed to determine remaining drug concentrations.  The amount of drug initially loaded into 
each bilayer wrap was 143±5.5 g.  At 1 week, 82% of the drug remained in the wrap and another 
16% was further released after 2 weeks.  By four weeks, the PLGA wrap had degraded 
significantly and intact wrap was not readily observable, thus the fibrous tissue that had 
incorporated into the wrap was analyzed.  The fibrous tissue, with traces of polymer, contained 
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Figure 3.10 Sunitinib concentrations in segments of porcine tissue collected at various 
postoperative time points.  Upper panel: Graphic representation of measured sunitinib 
concentrations in various segments of tissue collected at each time point.  Sunitinib 





3.3.7 Mechanical Properties 
 The Young’s modulus of elasticity is a measure of material stiffness.  Table 3.2 lists the 
Young’s modulus of elasticity for drug-free or drug-loaded nonporous monolayer PLGA constructs 
at various time points before and after incubation in 1X PBS.  Prior to incubation in PBS, the 
drug-free PLGA was elastic and flexible; after seven days in PBS the Young’s modulus increased 
indicating the PLGA became brittle with exposure to PBS.  Addition of sunitinib into the PLGA 
matrix further decreased the elasticity of the PLGA compared to the drug-free constructs as 
demonstrated by the increase in the Young’s modulus.  Also increased hydration time of the 
drug-loaded constructs (7 days) resulted in samples becoming so brittle that testing of elasticity 
failed, since the material fragmented when trying to place in the clamps of the Instron.  
3.4 Discussion 
The objective of this work was to develop a degradable, drug-loaded perivascular wrap that 
can direct drug release towards the graft and vascular wall to inhibit AV graft hyperplasia.  A 
bilayer wrap design employing a drug-free nonporous backing with either a porous or nonporous 
drug-loaded layer, was anticipated to provide unidirectional drug delivery towards the vessel while 
minimizing drug loss to surrounding extravascular tissue.  Limiting drug encroachment into 
surrounding nontarget tissues serves to mitigate the incidence of unwanted side effects and 
toxicities. 
The solvent casting and thermal phase inversion techniques used to fabricate the wraps in 

















Table 3.2 Effects of hydration on mechanical strength of monolithic PLGA 
 
Samples Days hydrated Young’s modulus 
(MPa) 
Drug-free PLGA 0 days 1.12±0.14 
Drug-free PLGA 1 day 2.53±0.69 
Drug-free PLGA 7 days 30.13±2.88 
Drug-loaded PLGA 0 days 40.15±0.35 
Drug-loaded PLGA 1 day 51.9±11.3 




relevant degradable polymers.  By altering the polymer concentration and nonsolvent system 
composition during casting, mechanical and structural properties can be manipulated.  For this 
application, polymer formulations were assigned to provide a strong but flexible construct for both 
layers that could be easily wrapped around a surgically accessed vessel.  An additional benefit of 
the fabrication methods described is the toxicologically benign solvent systems employed, 
predominantly acetone.   
Typically, harsh chlorinated solvents like chloroform or dichloromethane are used to create 
various PCL and PLGA matrices (21, 43-45).  High levels of residual solvent can still remain in 
these matrices even after extensive removal efforts (46) leading to potential toxicity risk.  There 
are currently no guidelines from the United States Pharmacopoeia (USP) regulating the maximum 
allowed residual solvent concentrations for these type of implantable materials (47). Therefore, 
employing solvent systems that are both i) facile to eliminate from the final polymer construct, and 
ii) innocuous if left behind in trace quantities, is desirable. 
For both bilayer wrap formulations, a nonporous backing was integrated into the design to 
help prevent drug loss to the surrounding tissue and to direct drug toward the target tissue. As 
seen in Figure 3.4, both nonporous PCL and PLGA membranes severely restricted diffusion of 
sunitinib and Oil red O (hydrophobic dye) over 72hrs.  In the case of PCL, sunitinib was detected 
in the lower media chamber but at a concentration one thousand times lower than that which was 
detected in the upper chamber.  The PCL layer created in the absence of porogen still had 
micropores formed as a result of the phase inversion process used to create the construct (Figure 
3.2). The micropores likely permit a faster diffusion of a drug through the bulk than through a 
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crystalline (nonporous) analog.  However, the nonporogen-created backing should still act as a 
barrier to decrease drug loss to the extravascular surroundings and thus promote a heavily 
favored net release towards the vessel. 
The versatility of the various wrap iterations permits incorporation of drug i) directly into the 
porous or nonporous polymer during casting or ii) into hydrogels that then can be incorporated into 
the porous polymer network.  Drug loaded into the porous layer would be expected to exhibit a 
steeper release profile than drug incorporated into the nonporous polymer network, given that the 
porogen-derived surface area would provide more opportunity for interaction with the solvent 
environment.  The hydrogel matrix used to load and suspend sunitinib in the porous layer was 
hyaluronic acid (HA)-based.  HA is a naturally occurring polysaccharide and a major component 
of the extracellular matrix (ECM) present in mammalian tissues (48).  This nonsulfonated, 
polyanionic GAG regulates cell motility and adhesion (49, 50), and is also implicated in maintaining 
water homeostasis within the ECM (51).  HA hydrogels have been developed that are 
biocompatible, degradable, and injectable by making thiolated HA derivatives that can be 
crosslinked with PEGDA (52).  Attempts were made to create a monolayer wrap from the HA 
directly but its mechanical properties proved unsuitable (not shown) for this application.  However, 
the hydrogels proved easy to infuse into the porous layer of the bilayer wraps and provided 
another means to influence the drug-release profiles.    
Release of sunitinib from the hydrogel was initially tested using both the salt (sunitinib malate) 
and free base forms. Sunitinib malate diffused swiftly out of the hydrogel with approximately 83% 
released in the first 24 hr (Figure 3.5). In the case of the free base, a slower 30 day release was 
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observed, at which point the hydrogel had degraded. The markedly dissimilar release profiles are 
likely due to the different interactions occurring between the salt and non-salt forms of sunitinib 
and the hydrogel.  HA found in the Glycosil hydrogel is thiol-functionalized via the available 
carboxylic acid functional groups, but only 42% of these moieties become modified (53).  At pH 7, 
the unreacted carboxylic acid groups are likely deprotonated while free base sunitinib (pKa~ 8.95 
(54)) should possess one protonated amine group, leading to an electrostatic interaction between 
the two.  Thus, release of free base sunitinib from this matrix is governed by ionic interactions, 
simple diffusion, and polymer degradation.  In the case of the malate salt form, sunitinib exhibits 
one ionized amine, but due to the presence of malate anion, the potential for ionic interaction via 
amines is reduced compared to the free base form, promoting faster diffusion.  The rapid burst of 
the malate salt from the hydrogel could lead to unacceptable drug levels and subsequent tissue 
toxicity; thus in proceeding studies with hydrogel, only the free base was incorporated.  
Breakdown of the HA hydrogel occurs via i) hydrolysis of the PEG acrylate esters that form 
after crosslinking, and ii) enzymatic cleaving of the glycosidic linkage by hyaluronidase (HAse).  
As expected, an initial faster drug release was observed when the hydrogel was incubated in the 
presence of HAse.  Since HAse would be endemic to the wound area after graft placement, a 
early faster release of sunitinib from the hydrogel-infused construct would be expected in vivo than 
what is observed in vitro in the absence of relevant enzymes and complex biological milieu. 
PCL degrades slowly in vivo (55-57), which is beneficial for particular applications (55, 58-61), 
such as orthopedic devices.  However, the current application would benefit from generally 
simultaneous matrix degradation and drug depletion, allowing for reapplication of drug to the AV 
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graft site. Polymer constructs were formed using lower molecular weight PCL as such constructs 
would have a faster degradation rate.  However, it was observed that the lower molecular weight 
constructs released most of the drug within one week, limiting their utility. 
Degradation rates of PLGA can be controlled by varying the co-monomer ratios of lactide and 
glycolide.  Increasing the ratio of lactide to glycolide decreases the degradation rate, due to the 
increasing hydrophobicity and crystallinity of the final polymer (42).  A porous/nonporous bilayer 
wrap and a nonporous/nonporous bilayer wrap were created using 50:50 PLGA, which exhibits the 
shortest possible degradative timeline.  When drug-laden hydrogel was infused into the porous 
layer of a PLGA porous/nonporous bilayer construct, an initial burst (68%) of sunitinib was 
observed during the first week, and remaining drug diffused out over the next week with complete 
release around 15 days (Figure 3.8).  Diffusion of drug out of the porous layer occurred before 
any notable polymer erosion was grossly observable.  In contrast, release kinetics of sunitinib 
from the nonporous/nonporous PLGA bilayer construct formulation were biphasic, exhibiting a 
continuous controlled release of drug for the first 30 days followed by a rapid release that 
exhausted after approximately 1 week.  Bulk erosion of the polymer network, which was grossly 
observable over this timeframe, likely permitted the rapid escape and depletion of drug.  
In vivo drug distribution studies were performed by placing a bilayer PLGA wrap consisting of 
a sunitinib-laden nonporous layer laminated to a drug-free nonporous layer around the jugular vein 
in a porcine model.  The adventitial layer of the vein was removed in order to initiate an injury 
response; the adventitia is also typically removed during hemodialysis arteriovenous graft 
placement.  At 1, 2, and 4 week postsurgical intervals, the highest levels of sunitinib in the tissue 
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were observed in vein segment that was in direct apposition to the wrap.  The drug 
concentrations obtained in these wrapped vein segments demonstrated levels higher than 
sunitinib’s in vitro effective IC50 against PDGF-stimulated smooth muscle cell proliferation at all 
time points.  By 2 weeks, the wrap showed signs of degradation, which likely resulted in 
increased drug release to the extravascular space. Drug was also detected, albeit in low 
concentrations, in the sternocleidomastoid muscle at 2 and 4 weeks.  These proof-of-concept 
experiments suggest that the nonporous drug-free backing was able to direct net drug release 
toward the vein in the early period after placement while diminishing inevitable loss to the 
surrounding extravascular tissue. 
Possible design improvements that could be made to inhibit further the loss of drug to the 
extravascular space include i) increasing the thickness and/or density of the drug-free nonporous 
backing, ii) increasing the ratio of lactide to glycolide polymer to decrease the degradation rate of 
the wrap, and iii) increasing the molecular weight of the utilized PLGA.  In addition, lower 
concentrations of drug could be loaded into the polymer so that drug release to the extravascular 
space would be below IC50 levels.  Of note, at 1 week, drug was detected in vein proximal of the 
wrapped segment.  However, the concentration was barely above detection limits for the assay 
and was not detectable at other time points.  It would be difficult to design a wrap that could 
prevent such release from the ends of the construct. 
Our in vitro studies showed that only approximately 10% of sunitinib was released from the 
wrap within the first week.  In vivo, approximately 18% of the drug load was released in week one.  
Drug release was also quicker in vivo at 2 and 4 weeks compared to in vitro.  The discrepancy in 
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the release rates is likely due to a faster degradation of PLGA in vivo.  Sink conditions with daily 
removal of the release media were performed for the in vitro experiments. However an acidic 
environment due to buildup of acidic degradation products (lactic and glycolic acids) is postulated 
to occur around the PLGA wrap in vivo.  The lowered pH would result in an autocatalytic effect 
accelerating polymer degradation (44, 62).  A total of 53.5 g of sunitinib released from the wrap 
is accounted for throughout the 4 weeks, which is only ~38% of the total 145 g of drug that was 
loaded in the wraps.  The drug unaccounted for was most likely eliminated from the vascular 
tissue by metabolism, diffusion through the vein into systemic circulation, or dispersed into 
surrounding tissue that was not analyzed.  Possibly due to the faster degradation rate of the wrap 
in vivo, the major drug burst that occurs because of polymer breakdown could have happened 
sooner than 4 weeks.  So at the four week time point, the majority of released drug due to 
degradation was already eliminated from the vascular tissue, which would explain why a greater 
amount of drug was unaccounted for.                           
Prior to formation into the polymer wrap constructs, the PLGA polymer is stiff.  However, 
after solvent casting into the monolithic films, the PLGA was ductile and could easily be wrapped 
around a blood vessel, and while not explicitly tested, even demonstrated properties of elastic 
recovery.  The increased ductility and improved handling characteristics are likely due to a 
change in the polymer chain conformation after casting, allowing for greater interchain mobility and 
altered gross material properties.  However, it was observed after both in vitro and in vivo testing 
that the PLGA constructs were much less flexible than what was observed prior to exposure to an 
aqueous environment.  To better understand this phenomenon, tensile testing was performed to 
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assess changes in stiffness of the PLGA constructs as a function of temporal in vitro hydration. 
The drug-free, nonporous PLGA was readily deformable and quite ductile when tested prior to 
hydration as demonstrated by the low Young’s modulus (Table 3.2).  Hydration of the PLGA over 
time caused the Young’s modulus to rapidly increase; the material became very brittle after 7 days 
hydration, revealing an anti-plasticizing effect of water that has been reported for PLGA films (63). 
The incorporation of sunitinib into the PLGA markedly decreased material extensibility, as shown 
by the increased stiffness compared to drug-free PLGA as was reported before with several drugs 
(64-66).  This increased stiffness was postulated to occur to pronounced drug-polymer 
interactions, reducing the mobility of the polymer chains in the matrix (21, 65, 67).  Hydration of 
the drug-laden PLGA polymer increased the Young’s modulus further. 
Possible explanations for the loss in extensibility upon hydration include i) thermodynamically 
driven polymer chain rearrangement to minimize contact with the infiltrating water molecules (63), 
and/or ii) the elimination of plasticization phenomena through the replacement of residual solvent 
molecules that enable high degrees of chain network mobility relative to water. As the material 
becomes hydrated, any residual solvent is displaced and the individual chains lose translational 
freedom.  Others have reported the phenomena of residual solvents like dichloromethane or 
chloroform altering mechanical properties in various degradable polymer materials (68, 69). 
Regardless of the cause of the change in mechanical properties after exposure to water, the 
increased stiffness may be particularly advantageous in decreasing hyperplasia at the vein-graft 
anastomosis.  It has been postulated that the enhanced circumferential tensile stress that occurs 
in a vein after introduction of arterial flow may significantly contribute to subsequent hyperplasia 
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formation (70, 71).  Others have shown that restricting the vein distension by application of 
perivascular supportive stents inhibits intimal hyperplasia in vein interposition grafts exposed to 
arterial flow (70-72).  In kind, the stiffening of the bilayer PLGA wrap after application around the 
vein-graft anastomosis could be beneficial in decreasing hyperplasia by inhibiting subsequent 
circumferential expansion. 
3.5 Conclusion 
A PLGA-based perivascular drug delivery system was created that is degradeable over a 
period of 30 days, provides early directed drug delivery due to the incorporation of an impermeable 
backing, is well-tolerated in vivo, and tunable to provide different drug release rates by either direct 
incorporation of drug, or by infusion of a drug-loaded hydrogel into a porous layer. Further work is 
needed however to slow the sudden degradation that resulted in a rapid release of drug after 30 
days.  The PLGA construct was also found to undergo a rapid increase in elastic modulus after in 
vivo placement that may be useful as a perivascular support against circumferential tensile stress 
in the vein. This study also revealed a novel interaction of the positively charged free base form of 
sunitinib with a selectively modified natural hydrogel, indicating for the first time, the hydrogel 
could be used for prolonged delivery of positively charged small molecule drugs. The PLGA 
construct presented in this study is a promising perivascular drug delivery system for the local 
treatment of AV graft NH and possibly other hyperplastic vascular disorders. 
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SUMMARY AND FUTURE WORK  
4.1 Summary 
In the US, more than 20% of all hemodialysis patient hospitalizations are due to vascular 
access dysfunction costing approximately 1 billion dollars annually (1).  The complex nature of 
the pathogenesis leading to AV graft stenosis makes treating the problem challenging.  A better 
understanding of the pathogenesis causing NH formation is emerging (2), but the molecular 
mechanisms of each pathogenic factor have not been delineated.  Inflammation is one common 
reoccurring factor and therefore likely plays an important role in NH (3-5).   
Based on the above observation, we investigated the involvement of inflammation in 
arteriovenous hemodialysis graft stenosis.  In our porcine AV graft model, macrophage and T-cell 
accumulation increased over the 7 week time course corresponding with an increase in the NH 
formation at the venous anastomosis.  Elevated expression of prominent cytokine/chemokines 
TNF- and MCP-1, was seen in vein-graft anastomotic tissue.  Both of these factors are known to 
influence NH development (6-8).  Our results have led us to conclude that recruitment and 
activation of inflammatory cells around the graft anastomoses likely plays an influential role in 
causing NH in AV ePTFE grafts used in hemodialysis. 
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An experimental anti-inflammatory drug (sEHI) targeting soluble epoxide hydrolase (sEH) to 
inhibit proinflammatory cytokine and chemokine release from primary macrophages was 
evaluated.  sEH converts anti-inflammatory EETs to less active DHETs. Inhibiting this conversion 
could prolong the anti-inflammatory activity of EETs.  sEH expression was observed in both 
vein-graft anastomotic tissue and primary macrophages, making it a potential target in treating NH.  
sEHI significantly inhibited LPS induced MCP-1 release and TNF- from primary macrophages, 
but did not significantly affect the release of MIP-1 or IL-6 (other proinflammatory 
cytokine/chemokines).  sEHI also inhibited MCP-1 release from bone-marrow macrophages 
(BMMs) in wild-type mice, but not inhibit release in sEH knockout mice suggesting sEHI 
attenuates MCP-1 release through a direct effect on sEH.  The nuclear translocation of NF-B 
was not decreased with sEHI, but the phosphorylation of jun-N-terminal kinase (JNK) was 
completely abrogated.  These findings indicate that sEHI could be useful in inhibiting 
inflammation seen around the anastomotic regions in AV grafts by inhibiting MCP-1 and TNF- not 
through the typical NF-B pathway, but instead via the JNK pathway.                   
We next developed a perivascular delivery system for controlled and directed release of 
sunitinib as a model drug, this system can be expanded to use other therapeutics for the treatment 
of AV graft stenosis.  A bilayer wrap design was employed containing a monolithic backing to 
provide unidirectional release and to prevent loss of drug to the extravascular space, and either a 
drug loaded non-porous layer, or a porous layer that could be infused with drug loaded hydrogel.  
The wrap was created using either polylactide-co-glycolide (PLGA) or polycaprolactone (PCL).  A 
wide range of release profiles was established by the use of the different polymers for construct 
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formation and by modifying the porosity and the molecular weight of the polymers. The control 
over release profile was further tuned by combining hydrogels with the porous polymers.  In vivo 
tissue pharmacokinetics was analyzed from the nonporous bilayer PLGA construct.  The backing 
directed drug release for at least the first week, but upon degradation allowed for some drug loss 
into the extravascular space after 2 weeks.  Sustained release of sunitinib at efficacious levels 
around the wrapped external jugular vein was accomplished for at least four weeks.  These 
promising results encourage further investigation into using this bilayer perivascular wrap loaded 
with sunitinib for the treatment of hemodialysis AV graft stenosis.       
4.2 Future Work 
4.2.1 sEHI Studies 
 We have examined sEH expression in primary human macrophages by confocal microscopy 
and western immunoblotting indicating the presence of the enzyme; however, this only indicates 
the presence of the enzyme and does not provide any information about sEH activity.  The sEH 
enzyme is a homodimer and each monomer is comprised of two distinct structural domains, each 
of which has catalytic activity.  The two catalytic domains, one on the N-terminus is a functional 
phosphatase and the second on the C-terminus has the epoxide hydrolase activity that catalyzes 
the addition of a water molecule to the epoxide resulting in the formation of a diol (9).  Borhan et 
al developed [
3
H]-trans-diphenyl-propene oxide (t-DPPO) in order to measure sEH activity by 
radiometric assay (10).  Epoxide hydrolase activity then can be measured in primary human 
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macrophage by using racemic [
3
H]-t-DPPO as a substrate and measuring the quantity of 
radioactive diol formed in the aqueous phase using a scintillation counter (11).   
 sEH catabolizes EETs into DHETs, which lack the anti-inflammatory effects of the parent 
compounds.  The sEH inhibitor should increase the production and accumulation of EETs by 
preventing EET turnover.  We have demonstrated that sEHI is working through sEH to lower 
MCP-1 secretion.  We postulate that the decrease in MCP-1 and TNF-α secretion is a result of 
the accumulation of EETS.  Obtaining the ratio of EETs to DHETs in primary macrophages after 
sEHI treatment would provide evidence that EETs are being accumulated and are the effective 
agents in decreasing MCP-1 and TNF- expression.  Macrophages would be pretreated with or 
without sEHI for 1 hr than stimulated with LPS for 24 hr.  Media would be collected and cell 
extracts would be produced to assay for 5,6 EETs, 8,9 EETs, 11,12 EETs, 14,15 EETs, 5,6 
DHETs, 8,9 DHETS, 11,12 DHETS, and 14,15 DHETS by using HPLC/negative mode 
electrospray ionization with a tandem mass spectral detection (12, 13).  EETs to DHETs ratios 
would be calculated.  These experiments would determine if 1) the sEH present in macrophages 
is active and 2) that EETs accumulation is occurring due to sEH inhibition. 
4.2.2 Perivascular Wrap Studies                            
 Early pathogenic factors such as vessel injury due to graft placement likely causes the 
maximal cellular activation within the first couple of days after placement requiring an initial burst 
of drug to combat these issues.  Repeated puncturing of the graft for dialysis and constant 
hemodynamic stresses makes NH formation in AV grafts a chronic problem that might require an 
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extended continuous release of drug to inhibit NH or repeated dosing for treatment. Here, we 
suggest a number of studies that will facilitate the translation of the bilayer perivascular wrap to 
clinical research. 
 We demonstrated the ability of our bilayer wrap design to deliver sunitinib around the 
wrapped vein at efficacious levels for at least 4 weeks, at which time the wrap had significantly 
degraded.  The ideal release kinetics for treatment of AV graft stenosis needs to be tested.  
Combination approaches incorporating drug directly into the porous PLGA during fabrication and 
infusing drug loaded hydrogel into the porous layer could be an initial starting point.  A larger 
initial burst could be attained from release of drug out of the hydrogel, followed by a slower 
extended release of drug diffusing out of the PLGA material until the material bulk degrades and 
releases the remainder of the drug.   
 By varying the copolymer composition of PLGA and molecular weight, the degradation time of 
PLGA, and subsequently, the release profile can be altered accordingly for the bilayer wrap.  
Increasing the ratio of lactide to glycolide and molecular weight has been demonstrated to slow 
down drug release and degradation due to increasing the hydrophobicity of the polymer matrix 
(14, 15).  Both of these concepts could be applied to the monolithic backing and drug loaded 
layer.  Increasing the lactide ratio in the PLGA used for the backing would prolong the ability of 
the backing to direct release and prevent extravascular drug loss.  Extended release of drug from 
the drug loaded layer could also be accomplished.  However, this also lowers the initial burst of 
drug from the matrix, which now may not reach effective levels to inhibit the early cellular 
responses that contribute to NH.  Incorporating polyethylene glycol (PEG), a water soluble 
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polymer, with PLGA can greatly enhance the initial burst (16, 17).  This permits increased water 
uptake into the matrix causing the creation of water-filled channels that triggers faster drug release 
rates.  Blending PEG and increasing the copolymer ratio of lactide to glycolide used in the PLGA 
in the drug loaded layer would likely allow for the initial drug burst and prolong release needed to 
treat NH formation in AV hemodialysis grafts.  The information gathered in these studies would 
aid in determining ways to improve the bilayer wrap design, which then could be tailored for 
perivascular delivery of other potential therapeutics for treatment of AV graft stenosis.    
After determining the best wrap design to attain the desired release kinetics of sunitinib for 
NH prevention, efficacy studies of the bilayer wrap in our porcine AV graft model (18, 19) would be 
tested.  Yorkshire cross domestic swine, weighing 30 kg would be used for these studies.  
Expanded PTFE grafts (spiral re-enforced, 7-cm length, 6-mm internal diameter) would be placed 
between the common carotid artery and the ipsilateral external jugular vein bilaterally.  Sunitinib 
loaded and control bilayer wraps would be placed around the venous anastomoses.  One side 
would receive a drug loaded wrap and the other side would receive an unloaded wrap that serves 
as a control.  Doppler ultrasound would be used to monitor graft patency weekly.  Six weeks 
after graft placement, the animals would be euthanized and the grafts would be explanted en bloc 
along with 1-2 cm of the adjacent native blood vessels.  Explanted tissue would be subjected to (i) 
tissue pharmacokinetics and (ii) histological analysis for NH quantification using H&E and Van 
Gieson stain, as previously done in our lab (18).  Different animals would be utilized in order to do 
both.  These studies will determine if sunitinib delivered perivascularly is an effective treatment 
option to inhibit NH formation in AV grafts.         
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 Tissue pharmacokinetics would be performed similar to what was previously done in our lab 
(20).  Following explantation, the tissue block with any remaining wrap would be immediately 
placed in sodium phosphate buffer (100 mM, pH 7.4) and flash-frozen.  Both the venous and 
arterial anastomosis would be cut cross-sectionally into five segments of 1-cm in length each and 
weighed.  Any remaining wrap would be removed from the vein-graft anastomosis and weighed.  
Interstitial tissues around the anastomoses would be sampled with their distances from the 
anastomosis measured.  Sunitinib would be extracted from each tissue sample and any 
remaining wrap, and assayed using LC-MS/MS.  The extraction and LC-MS/MS protocol have 
been described in Chapter 3.  Pharmacokinetic studies will clarify the concentrations of drug 
needed to be loaded to maintain adequate efficacious tissue levels and indicate if or when 
repeated dosing options are needed to sustain these levels for treatment.  This will lead towards 
the optimal design of a drug delivery system for prevention of NH. 
 Future work to be considered is delivery of therapeutics that can target the chemokine MCP-1 
or its receptor CCR2; the work presented in this thesis suggests such treatments could be 
beneficial in inhibiting arteriovenous graft stenosis.  We demonstrated the upregulation of this 
proinflammatory mediator at the vein-graft anastomosis in our porcine AV graft model.  A variety 
of potential therapeutics has been developed that target MCP-1/CCR2.  Zhang et al. created a 
plasmid coding for N-terminal deletion mutant of MCP-1 called 7-ND (21).  This mutant MCP-1 
binds to the CCR2 receptor and has been shown to inhibit MCP-1 mediated monocyte chemotaxis 
(21).  7-ND has been effective in inhibiting hyperplasia development in different arterial injury 
animal models (22-24).  Short interfering RNA (siRNA) targeting CCR2 has been developed and 
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shown to be successful in decreasing CCR2 mRNA levels in monocytes, which led to a decrease 
in the accumulation of these monocytes into sites of inflammation (25).  A small molecule 
indazole derivative, bindarit, has been shown to be efficacious in preventing restenosis in porcine 
coronary arteries after stenting (26).  Bindarit selectively inhibits the production of MCP 
chemokines and IL-12, likely through the inhibition of a subpopulation of NF-B proteins (27).  
These therapeutic agents could be incorporated into the perivascular wrap for local delivery to 
prevent hyperplasia formation in AV grafts used for hemodialysis.                                            
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AUTOLOGUS ADIPOSE TISSUE DEPOTS TO INHIBIT 
ARTERIOVENOUS GRAFT STENOSIS 
A.1 Introduction 
Adipose tissue (AT) is now considered a complex and highly metabolically active endocrine 
organ.  AT is primarily composed of adipocytes, but also consists of macrophages, fibroblasts, 
and mesenchymal stem cells (1).  White and brown AT are the two types of AT found in humans.  
There are two categories of white AT: i) subcutaneous, and ii) visceral which is also known as 
organ fat.  Visceral AT typically contains increased numbers of resident inflammatory cells 
compared to subcutaneous AT, giving it a more inflammatory phenotype but the exact reason is 
for this is not known (2, 3). To illustrate this point, monocyte chemotactic protein-1 (MCP-1) 
release was greater in human visceral AT than subcutaneous AT (2) and coronary artery AT had 
greater expression of pro-inflammatory mediators, such as MCP-1, TNF-, and IL-6 than 
subcutaneous AT (4).  Ohman et al. verified this concept in vivo, visceral AT transplanted from 
ApoE-/- mice into recipient ApoE-/- mice developed significantly more atherosclerosis compared to 
those mice transplanted with subcutaneous AT even though plasma levels of adiponectin were 
similar between the two (5).    
AT generates many proteins, including leptin, MCP-1, TNF-, IL-6, IL-10, resistin, and 
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adiponectin (1).  Adiponectin, a 29 kDa protein secreted primarily by AT has potent 
anti-inflammatory properties.  The adiponectin monomer oligomerizes to form low, medium, or 
high molecular weight (LMW, MMW, or HMW) multimeric complexes in blood.(6).  The HMW 
isoform of adiponectin has been associated with good cardiovascular outcomes and vascular 
protection (7-10).  For example, low serum levels of HMW adiponectin correlated with 
cardiovascular events in patients with coronary artery disease (11).  Adiponectin possesses 
many functions that may be valuable in preventing hyperplasia including the inhibition of i) 
TNF--stimulated expression of adhesion molecules, such as intracellular adhesion molecule-1, 
vascular cellular adhesion molecule-1, and E-selectin (12), ii) activation of NF-B in 
TNF--stimulated endothelial cells (13), and iii) IL-6 and TNF- release from LPS-stimulated 
macrophages (14). Adiponectin also iv) promotes the conversion of macrophages from the 
classically activated (pro-inflammatory) state to the alternatively activated (anti-inflammatory) state 
(15), v) induces expression of the anti-inflammatory IL-10 from human macrophages (16), vi) 
inhibits SMC proliferation (17), and vii) inhibits platelet activation (18).  Recombinant adiponectin 
delivered perivascularly using a gelatin hydrogel inhibited neointimal hyperplasia in an artery wire 
injury model in adiponectin knockout mice.  Similarly, transplantation of subcutaneous AT around 
the injured artery also inhibited hyperplasia (19).  Such findings suggest that adiponectin is a 
vasculoprotective molecule and adiponectin supplementation could be beneficial for treatment of 
vascular hyperplasia.   
Glitazone (thiazolidinediones) drugs are anti-diabetic insulin-sensitizer drugs that promote 
insulin-dependent glucose uptake into target tissues.  Pioglitazone and rosiglitazone are currently 
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FDA-approved for treatment of diabetes.  The glitazone drugs preferentially bind to the  isoforms 
of the nuclear peroxisome-proliferator activator receptors (PPAR) but pioglitazone can also 
activate PPAR.  The PPAR proteins are transcription factors that control the expression of 
genes that regulate lipid and glucose metabolism and cellular proliferation, apoptosis, and 
anti-inflammatory responses.  The PPARs are expressed in many cell types including AT, 
macrophages, and cells of the vasculature.  PPAR is most highly expressed in AT whereas 
PPAR is more highly expressed in cells of the vasculature including smooth muscle and 
endothelial cells.  These drugs can also bind to the outer mitochondrial membrane protein 
mitoNEET, which effects mitochondrial function by inhibiting the oxidative capacity of the 
mitochondria (20, 21).  Therefore, the biological effects of glitazones may not be mediated just 
through PPARactivation.   
Glitazones have potent anti-inflammatory effects such as i) the inhibition of SMC proliferation 
(22, 23), ii) inhibition of pro-inflammatory cytokine release, such as MCP-1 and TNF- (24, 25), iii) 
inhibition of platelet aggregation (26, 27), and iv) attenuation of matrix metalloproteinase 
expression (28, 29).  Another important aspect of these drugs is that they are potent inducers of 
adiponectin protein expression from AT.  Tsuchida et al. demonstrated that rosiglitazone 
administered orally in obese diabetic KKAy mice could increase both serum adiponectin 
concentration and the ratio of HMW multimers of adiponectin to total adiponectin (30).  Of 
particular relevance to the current work, subcutaneous AT explants from obese patients exposed 
to pioglitazone in vitro had increased adiponectin secretion compared to non-drug treated AT (31).  
With this knowledge, we propose that treating autologous AT explants with glitazone drug and 
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then transplanting the AT around the venous anastomosis of AV grafts would trigger adiponectin 
secretion from the AT.  The adiponectin would then interact with adiponectin receptors on the 
medial smooth muscle cells and adventitial fibroblasts to inhibit proliferation and migration, and 
also on the endothelium to induce nitric oxide release and inhibit procoagulant expression. 
Glitazone drugs are lipophilic (hydrophobic) molecules, as indicated by Log P values greater than 
2.5 (32),that should incorporate readily into the hydrophobic AT explants.  Thus, we also propose 
that subcutaneous AT explants could act as a controlled delivery depot, providing sustained 
release of the vasculoprotective glitazones, which then could also inhibit graft hyperplasia by 
decreasing inflammation and inhibiting fibroblast and smooth muscle cell proliferation.               
We report in vitro experiments testing the feasibility of using autologous subcutaneous AT 
explants treated with rosiglitazone to i) stimulate the production of adiponectin, and ii) to provide 
controlled delivery of rosiglitazone.  Additionally, in vitro anti-inflammatory effects of the AT 
explants on SMC proliferation and MCP-1 release from AT are reported. 
A.2 Materials and Methods 
A.2.1. Materials 
 Rosiglitazone and the deuterated internal standard rosiglitazone-D3 were purchased from 
Toronto Research Chemicals (North York, ON, Canada).  HEPES, insulin, and transferrin were 
all purchased from Invitrogen.  Dexamethasone, acetonitrile (ACN), methyl-tert-butyl ether 




A.2.2. AT Collection and Culture 
Abdominal subcutaneous AT left over after lipoaspiration or slab excision during breast 
reconstruction surgeries was obtained from human patients.  The AT was de-identified and 
obtained under a blanket IRB approval for use of tissue samples collected during surgery that 
would normally be discarded.  Lipoaspirated AT was present in small pieces (approximately 2-4 
mm globules).  The slab AT was excised from the skin and minced into small pieces before 
culturing.  Powdered rosiglitazone was thoroughly but gently mixed directly into the AT explants 
using a sterile spatula to yield a concentration of 1000 M (calculated using the conversion of 1g 
AT = 1 mL). Untreated AT explants were physically mixed in the same fashion but in the absence 
of powdered drug (control).  AT explants were cultured in low glucose Dulbecco’s modified 
Eagle’s medium (DMEM, Invitrogen) containing HEPES (25 mM), insulin (1 nM), transferrin (10 
g/mL), dexamethasone (30 nM), and antibiotics. For thirteen days media was removed and 
replaced with fresh media approximately every 2 days.  The conditioned media was frozen 
immediately at -80 
o
C then assayed by ELISA for adiponectin (R&D Systems, Minneapolis, MN) 
and MCP-1 (PeproTech, Rocky Hill, NJ) in accordance with the manufacturer’s instructions.   
The conditioned media samples for HPLC MS/MS analysis of rosiglitazone were spiked with 
rosiglitazone-D3 (internal standard (IS)) at known concentrations to monitor recovery efficiency.  
Rosiglitazone and IS were extracted from the conditioned media by vortexing with 1:1 
MTBE:1-chlorobutane for 2 min and centrifugation at 25 
o
C at 2000xg for 15 min.  The organic 
layer was collected and solvent evaporated at 42 
o
C overnight then reconstituted in 
acetonitrile-deionized H2O (65:35, v/v) running buffer containing 0.1% formic acid. 
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A.2.3. Drug Sample Analysis by HPLC Tandem Mass Spectrometry 
 The sample analysis protocol was modified from a previously published protocol (33).  The 
analytical separation of rosiglitazone and rosiglitazone-D3 were performed using an Atlantis dC18 
column (2.1 x 30 mm, 3.0 m) ( Waters Corp., Milford, MA), protected by a 4mm x 2mm C18 
packed guard column (Phenomenex) at 25 
o
C on an Acquity 2695 HPLC system (Waters Corp.) 
equipped with a refrigerated autosampler.  The mobile phase consisted of acetonitrile–deionized 
H2O (65:35, v/v) containing 0.1% formic acid and was ran isocratically at a flow rate of 0.3 mL/min.  
Sample run times were 6 min followed by a 2-min needle wash process to prevent possible 
carryover.  The IS and rosiglitazone eluted at 0.69 min.   
A triple quadropole tandem mass spectrometer (Micromass® Quattro II, Waters Corp.) 
equipped with an electrospray ionization (ESI) interface was used for analytical detection.  
Quantification was performed in positive-ion mode using multiple reaction monitoring (MRM) of the 
transition masses of rosiglitazone (m/z 358.3 → 135) and the internal standard rosiglitazone-D3 
(m/z 361.1 → 138).  Instrument parameters were optimized for simultaneous detection of both 
rosiglitazone and the IS.  The capillary energy was set at 3.50 kV, cone voltage at 35 V, extractor 
at 3 V, source block temp at 125 
o
C, desolvation temperature at 325 
o
C, and the optimal collision 
energy was determined to be 27 V.  Calibration curves for both rosiglitazone and rosiglitazone-D3 
were established using standard samples at seven concentrations ranging from 1000 ng/mL to 5 
ng/mL.  The coefficient of determination (r
2
) from a least squares linear regression was found to 
be 0.999 for both rosiglitazone and rosiglitazone-D3.  Validation for accuracy and precision of the 
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HPLC MS/MS method was performed using spiked samples of media.  Sample recovery of >80% 
was attained, as determined by percent recovery of the IS. 
A.2.4. Smooth Muscle Cell Proliferation 
Human venous vascular SMCs were seeded in 96-well tissue culture plates at 5000 cells/well 
in SMC media (Cascade Biologicals) without serum for 48 hr to quiesce the cells.  Media was 
replaced with conditioned media (1:10 dilution) from either rosiglitazone-treated or untreated AT 
collected at various time points. Platelet-derived growth factor-BB (PDGF-BB, 50 ng/mL) was 
added to stimulate cell proliferation and cells were incubated for 48 hr whereupon cell proliferation 
was measured by a fluorescence-based DNA-binding assay (CyQuant, Invitrogen).    
A.3 Results 
A.3.1. Increased Adiponectin Secretion from Rosiglitazone-treated AT 
Increased adiponectin secretion was observed from human AT mixed with rosiglitazone 
compared to control untreated AT: adiponectin levels were doubled by four days and elevated 
3-fold above levels from untreated AT at eight days (Figure A.1). 
A.3.2. In Vitro Drug Release of Rosiglitazone from AT 
The cumulative release of rosiglitazone from AT is shown in Figure A.2.  Approximately 20% 
of drug is released within the first 2 days followed by a slower controlled release over the next 
















Figure A.1  Release of adiponectin from human AT treated with (red) or without (blue) 
rosiglitazone at various time points.  Media was removed every 2 days analyzed for total 
adiponectin by ELISA.  Asterisks denote statistically significant difference (*<0.01 or **<0.001) 


















































A.3.3. Attenuation of MCP-1 Release from Rosiglitazone-treated AT 
Using media from the same experiment that was assessed for adiponectin release, it was 
observed that MCP-1 release from the rosiglitazone-treated AT was significantly decreased 
compared to untreated AT at day two and four (Figure A.3).  By day four, secretion of MCP-1 was 
diminished in both treated and untreated AT yet MCP-1 release was still significantly lower from 
rosiglitazone-treated AT compared to control. 
A.3.4. Conditioned Media from AT Inhibits SMC Proliferation 
 The conditioned media collected at days 2 and 8 from both untreated- and 
rosiglitazone-treated AT significantly inhibited PDGF-stimulated SMC proliferation (p<0.05) (Figure 
A.4).   
 A trend towards greater inhibition of SMC prolieration with conditioned media from 
rosiglitazone-treated AT was observed but this did not reach significance.  In addition, 
proliferation of SMC exposed to conditioned media from AT incubated for 8 days with rosiglitazone 
was the same as that seen in SMC incubated in the absence of PDGF.  The concentrations of 
adiponectin and rosiglitazone determined in the conditioned media at days 2 and 8 are listed in the 
table in Figure A.3.  Conditioned media from rosiglitazone-stimulated AT at these time points had 
similar concentrations of drug, but at day eight adiponectin levels were approximately 16 times 



















Figure A.3  Release of MCP-1 from human AT treated with (red) or without (blue) rosiglitazone at 
various time points.  Media was removed every 2 days and analyzed for MCP-1 by ELISA.  
Asterisks denote statistically significant difference (*<0.01 or **<0.001) between control and 














Figure A.4 PDGF stimulated SMC proliferation was inhibited by conditioned media at days 2 and 
8 from untreated- (control) or rosiglitazone treated-AT.  AT was from one patient.  Adiponectin 
and rosiglitazone concentrations in conditioned media are listed in the table.  Cell proliferation in 
samples treated with conditioned media from untreated- and rosiglitazone-treated AT was 




We have hypothesized that AT could serve as an autologous drug delivery depot for glitazone 
drugs and as a biofactory for endogenously produced adiponectin.  Glitazone drugs are 
themselves vasculoprotective and induce adiponectin which also has vasculoprotective properties.  
The primary objective of these initial studies was to characterize whether dry rosiglitazone (in the 
absence of added solvent) mixed in AT would induce adiponectin and inhibit inflammation.  The 
long-term goal of our studies is to determine if autologous AT mixed with glitazone then 
transplanted back to the venous anastomosis of arteriovenous hemodialysis grafts in a porcine 
model would inhibit graft stenosis.  
 Several studies have reported the ability of rosiglitazone to stimulate adiponectin secretion 
from AT in vitro and in vivo (34-38).  In the previous in vitro studies, the rosiglitazone was 
dissolved in solvent and added to media surrounding the AT explants. In the present study, we 
examined if powdered rosiglitazone, not dissolved in solvent, could induce adiponectin after 
mixing into human AT.  Solvents were omitted since the final goal is to reapply the drug-treated AT 
as autologous transplants and solvents may negatively impact AT viability.  Rosiglitazone 
stimulated the release of adiponectin by 4 days and adiponectin expression remained elevated at 
eight days (Figure A.1).  Cabanelas et al. reported a significant decrease in adiponectin release 
at 48 hours after incubating rosiglitazone with subcutaneous rat AT compared to untreated AT (39).  
However, no time points later than 48 hr were investigated.  We did not examine adiponectin 
release at time points earlier than 48 hr thus adiponectin expression may have been decreased at 
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that time point.  Our work did not investigate why rosiglitazone required up to four days to induce 
adiponectin secretion.  
MCP-1 (CCL2), a CC chemokine, is a potent chemoattractant that recruits peripheral 
monocytes and memory T-cells into sites of inflammation (40).  Besides monocytes/macrophages, 
many other cell types secrete MCP-1 including T-cells, endothelial cells, SMC, and fibroblasts (41); 
all cell types that likely play a role in hyperplasia formation.  Increased MCP-1 expression occurs 
in many experimental models of neointimal hyperplasia.  For instance, up-regulation of  MCP-1 
appeared early in arteries after balloon injury in hypercholesterolemic rabbits (42) and femoral 
artery interpositional venous bypass grafting in rats (43).  Inhibiting MCP-1 using either a 
neutralizing antibody for MCP-1 or a plasmid coding for N-terminal deletion mutant MCP-1 has 
been effective in diminishing neointimal hyperplasia in different animal models of arterial injury 
(44-46).  MCP-1 is also expressed in AT and expression levels have been found to correlate 
positively with the degree of obesity (47, 48).  Incubating AT with rosiglitazone significantly 
inhibited MCP-1 release at days 2 and 4 compared to control untreated AT (Figure A.2.).  
However, MCP-1 release was noticeably decreased whether rosiglitazone was present or not by 
day four.  It is likely that dexamethasone, a typical ingredient of standard adipose culture media, 
inhibited release at these later time points.  Further studies are needed to test the effect of 
rosiglitazone on MCP-1 release from AT in the absence of dexamethasone.  
Proliferating and migrating SMCs and myofibroblasts compose the majority of cells that 
populate hyperplasia in AV grafts.  Several studies have reported that either rosiglitazone or 
adiponectin can attenuate SMC proliferation (17, 23, 49-52).  Rosiglitazone binds to PPARγand 
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induces apoptosis of SMC and inhibit SMC proliferation and migration (23, 53) which likely 
mediates the inhibition of transcription factor function critical for SMC proliferation.  Adiponectin 
hinders SMC proliferation by binding to several mitogenic growth factors, such as platelet derived 
growth factor-BB (PDGF-BB) and basic fibroblast growth factor (FGF), preventing them from 
interacting with their respective receptors.  In this study, we examined the effect of conditioned 
media from untreated control AT and rosiglitazone-treated AT on human SMC proliferation 
stimulated by PDGF.  Conditioned media removed from both control and rosiglitazone-treated AT 
at days two and eight significantly inhibited SMC proliferation (Figure A.4).  These data indicate 
that rosiglitazone-treated AT depots could be effective in preventing SMC proliferation, which 
would be valuable in preventing AV graft hyperplasia.  Further studies are needed to define 
exactly which AT-derived mediators are participating in the SMC inhibition. 
In addition to AT serving as a bioreactor for the production of adiponectin, our approach has 
AT also serving as a drug delivery depot for controlled release of rosiglitazone.  Thus the release 
of rosiglitazone from AT was examined.  After adding powdered rosiglitazone to the AT, the AT 
was placed in culture media and the media was examined longitudinally for presence of 
rosiglitazone by LC/MS/MS.  Rosiglitazone was detected in the media early and also slowly 
released over time suggesting that the AT can serve as a drug release depot.  The effects of 
rosiglitazone alone on SMC proliferation was not tested in these studies but previously 
rosiglitazone was reported to completely inhibit PDGF-induced SMC proliferation at a 
concentration of 1 M (54).  However, in our studies, conditioned media that contained 1.9 M 
rosiglitazone (Day 2 Rosi in Fig. A.3) resulted in approximately a 50% reduction in PDGF-induced 
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SMC proliferation.  A similar concentration of rosiglitazone was detected in conditioned media 
collected at eight days but with four times the concentration of adiponectin.  This eight day media 
completely inhibited SMC proliferation suggesting that adiponectin was playing an important role 
in the observed inhibitory effects of the AT conditioned media.  Recently, a release profile for 
rosiglitazone from an injectable hydrogel made from a mixture of naturally derived materials 
(chitosan, teleostean and oxidized dextran) was described (55).  Rosiglitazone was dissolved in 
DMSO before loading into the hydrogel and about 80% of the drug was released by day 14. In 
contrast, our results showed much slower release from AT, which is likely due to the greater 
hydrophobicity of the AT delivery depot and the lack of DMSO solvent.  Hydrophobic molecules 
like rosiglitazone (experimental Log P 2.78 (32) incorporate more readily into the hydrophobic AT 
depot, which allows for slower release.  Hence, our data indicates AT can act as an autologous 
controlled sustained delivery depot for rosiglitazone or other hydrophobic drugs that may be 
considered for future use.                                                             
The initial data presented in this study is from a limited number of patient samples (n=1) and 
AT explants from additional patients are needed to confirm these findings.  Also, total adiponectin 
levels were measured, which does not provide information on the type of MW isoforms of 
adiponectin being produced.  In future studies, the MW of adiponectin being secreted will be 
characterized by ELISAs specific for the various MW adiponectin complexes or by native 
polyacrylamide gel electrophoresis.  Another caveat with this study is that the remaining amount 
of drug in the AT depots was not quantified.  For future in vitro drug release experiments, any 
remaining drug will be extracted and quantified by HPLC MS/MS to determine how much remains 
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within the AT.                   
This study is the first to report the study of autologous AT explants as means to deliver drug 
and adiponectin.  These preliminary in vitro studies indicate that i) powdered rosiglitazone can 
induce sustained production of adiponectin when mixed with AT explants, ii) AT can act as a drug 
delivery depot, and iii) rosiglitazone and/or adiponectin released from AT have potent 
anti-inflammatory and anti-proliferative properties that could be beneficial in deterring vascular 
hyperplasia development. 
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